

Introduction to Clinical Pharmacology 11th Edition PDF

Visit the link below to download the full version of the ebook

[DOWNLOAD NOW](#)

EDITION

11

Introduction to Clinical Pharmacology

Visovsky Zambroski Hosler



Evolve*

Student
Access



Scan to Download
or Type the Link

ebook.ac/introduction11e

EDITION

11

Introduction to Clinical Pharmacology

Visovsky Zambroski Hosler



Evolve®


Student Resources on Evolve
Access Code Inside

Evolve®

YOU'VE JUST PURCHASED MORE THAN A TEXTBOOK!

Enhance your learning with Evolve Student Resources.

These online study tools and exercises can help deepen your understanding of textbook content so you can be more prepared for class, perform better on exams, and succeed in your course.



Activate the complete learning experience that comes with each NEW textbook purchase by registering with your scratch-off access code at

<http://evolve.elsevier.com/Visovsky/LPNpharmacology/>

If your school uses its own Learning Management System, your resources may be delivered on that platform. Consult with your instructor.

If you rented or purchased a used book and the scratch-off code at right has already been revealed, the code may have been used and cannot be re-used for registration. To purchase a new code to access these valuable study resources, simply follow the link above.

Place
Sticker
Here

REGISTER TODAY!



You can now purchase Elsevier products on Evolve!
Go to evolve.elsevier.com/shop to search and browse for products.

EDITION

11

Introduction to Clinical Pharmacology

Constance G. Visovsky, PhD, RN, ACNP, FAAN

Professor and Lewis & Leona Hughes Endowed Chair
in Nursing Science
College of Nursing
University of South Florida
Tampa, Florida

Cheryl H. Zambroski, PhD, RN

Associate Professor
College of Nursing
University of South Florida
Tampa, Florida

Shirley Meier Hosler, RN, BSN, MSN

Adjunct Faculty
Santa Fe Community College
Santa Fe, New Mexico



Elsevier
3251 Riverport Lane
St. Louis, Missouri 63043

INTRODUCTION TO CLINICAL PHARMACOLOGY, 11TH EDITION

ISBN: 978-0-443-11336-9

Copyright © 2025 by Elsevier, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notice

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Previous editions copyrighted 2016, 2019, and 2022.

International Standard Book Number: 978-0-443-11336-9

Senior Content Strategist: Brandi Graham
Content Development Specialist: Andrew Schubert
Publishing Services Manager: Deepthi Unni
Project Manager: Nayagi Anandan
Design Direction: Renee Duenow

Printed in India

Last digit is the print number: 9 8 7 6 5 4 3 2 1



Contributor

M. Linda Workman, PhD, RN, FAAN
Visiting Professor
Case Western Reserve University
Cleveland, Ohio

Reviewers

Larissa Brown, MSN, RN

Educator
Three Rivers College
Poplar Bluff, Missouri

Tammy R. Dean, BSN, RN

Director
Prince William County School of Practical Nursing
Manassas, Virginia

Diane Duffy, RN, BSN, MEd

Practical Nursing Director
Chisholm Trail Technology Center
Omega, Oklahoma

James Graves, PharmD, MBA

University of Missouri Health Care
Columbia, Missouri

James D. Holland, PhD, RN, CNL, RRT, RCP

Associate Dean of Nursing and Allied Health
North Florida College
Madison, Florida

Denise King, MSN, RN

Practical Nursing Program Lead Instructor
Beaufort County Community College
Washington, North Carolina

Jill Kirk, RN, BSN

Director of Nursing
Tennessee College of Applied Technology
Paris, Tennessee

Leslie Merritts, RN, BSN

Director of Practical Nursing
Treasure Coast Technical College
Vero Beach, Florida

Tina Spagnola, MSN, RN, NPD-BC, NE-BC

Program Chair & Nursing Instructor
Pinellas Technical College
Clearwater, Florida

Preface

This 11th edition of *Introduction to Clinical Pharmacology* offers updated drug information from a team of committed authors who have years of experience in clinical care, in nursing education, and in teaching pharmacology content. Understanding and retaining knowledge of pharmacology are critical components of nursing care and patient safety. The author team strived to make the pharmacology learning experience one that combines updated information with drug safety cues and memory joggers to initiate information recall. In addition, features such as Lifespan Considerations link the information to care of the patient across all ages as appropriate. Each chapter contains a brief review of the body system and potential health problems. This format promotes high levels of content retention and also incorporates the newest NCLEX® testing blueprint format.

This textbook is written using the second person throughout to engage students and help them understand the nursing responsibilities required for use in the clinical setting. The textbook's new organization and style are intended to engage students and help them develop an in-depth understanding of the "need to know" content that is critical for safely administering medications in all environments in which licensed practical nurses/vocational nurses (LPNs/VNs) are employed. The components of the nursing process aligning with the LPN/LVN role are emphasized. All chapters, test questions, case studies, and illustrations have been greatly expanded to explain drug actions and techniques for administration. In addition, the 11th edition has an added chapter focused on drugs for anesthesia and analgesia and cancer therapeutics.

The textbook uses current terminology for education and healthcare practice. For example, more settings include nurse practitioners and physician assistants as legal prescribers in addition to the physician. To reflect this change, the term healthcare provider is used throughout. When discussing individuals receiving nursing care, the authors prefer the use of the term *patient* as opposed to the term *client*.

Learning Outcomes now replace Chapter Objectives. These outcomes concisely and clearly let the student know which content represents the *highest priority* for safe medication administration. All drugs and drug categories no longer in common usage, or those that do not apply to the LPN/VN role, have been eliminated. The textbook also helps students learn to make use of prevailing technology in drug

delivery. Internet resources and references have been identified and highlighted within the Bookmark This feature.

Newly created drug tables are divided by drug category and organized to provide students with concise access to mechanisms, common adult drug dosages, and essential nursing implications for administration and patient teaching. Key terms critical for pharmacology are listed at the beginning of each chapter and include phonetic pronunciations, definitions, and page numbers where each term is first used. This textbook takes advantage of the use of medical and nonpharmacologic terminology, with short definitions placed alongside the terms and in the Glossary to aid student reading and retention.

Throughout this textbook, ensuring patient safety remains a major theme. The safety features are the Top Tip for Safety boxes that highlight very specific precautions, unusual drug dosages, or critical nursing interventions. This author team deeply believes that it is critical to provide patient safety information to reduce drug errors. In addition, patients and families who understand the why of directions are more likely to adhere to them. Toward this purpose, nursing actions are accompanied by the appropriate rationale. In the discussion of each drug category, the sections on patient and family teaching provide direct examples of exactly what to teach patients and families, as well as the rationales for why these actions or precautions are necessary. Specific content on Lifespan Considerations for drug administration related to older adults and pediatric patients and for pregnancy and lactation are appropriately placed for maximum retention.

Other user-friendly learning techniques provided in this streamlined and updated edition include features such as Memory Jogger and mnemonics. End-of-chapter review questions have been changed to reflect the latest NCLEX® format for developing clinical judgment, including multiple-choice, "select all that apply," and Next-Generation NCLEX-style questions. These formats help the student to think through responses rather than focus on rote memorization. All clinical chapters have newly developed case studies designed to help students learn to apply specific content.

The Student Study Guide has been revised. The instructor's TEACH resource is completely updated based on the revised Learning Outcomes for each chapter. The test bank has also been revised with newly formatted Next-Generation NCLEX® questions that

require the student to apply knowledge and prepare for the NCLEX® examination.

ORGANIZATION AND FEATURES

This textbook has been updated to include updated drugs, to remove drugs and terms that are no longer used in practice, and to add tables for each drug classification that list common drugs for each class and normal adult dosage ranges. Throughout this text, medications are referred to as drugs, and the drug prescriber is called the healthcare provider because this can be a physician, advanced practice nurse, certified registered nurse anesthetist, or physician's assistant. The text has been reorganized into three units totaling 23 chapters to streamline access to specific content areas. Chapter-ending Get Ready for Next-Generation NCLEX® Examination questions have been updated and revised throughout the text and use mostly application questions and Next-Generation NCLEX-style questions to provide students with practice in answering these types of examination questions.

UNIT I

The first unit provides an overview of general principles of pharmacology, including the nursing process as it relates to drug administration, and safe practices in drug administration that set the knowledge base for understanding specific drug categories. For example, this edition includes information on unique aspects of the contemporary LPN/LVN practice environment, including working in teams with medication assistants, the registered nurse, the healthcare provider, and other healthcare professionals.

Safe practice is accentuated throughout **Chapter 1**, with a guide to planning and giving drugs to patients. The updated *9 Rights of Drug Administration* is presented in detail and includes the right of the patient to refuse a drug. Although giving drugs properly is important, equally important are evaluating the expected drug response, understanding common side effects, and knowing how to handle adverse events from drugs.

In **Chapter 2**, the legal, regulatory, and ethical content related to giving drugs in the LPN/LVN role has been updated to include a thorough discussion of schedule drugs, drug diversion, and a distinction between addiction, drug abuse and misuse, and physical dependence. Technology-associated patient identification, drug orders, and the giving and recording of drugs in either a standard Kardex or electronic health record are covered. In **Chapter 3**, the student is acquainted with the Principles of Pharmacology, including drug absorption, distribution, metabolism and elimination to provide a basis for the drug knowledge in the following chapters.

UNIT II

Unit II is dedicated to the principles and calculations related to drug administration. The beginning of the

unit focuses on drug calculation methods, such as fractions, ratio, and proportion, and dimensional analyses to give an in-depth review of drug calculation approaches used in different educational settings. Unit II is concerned with drug calculation, preparation, and administration. LPN/LVNs work in a variety of settings, including acute care, but are often employed in assisted nursing centers, nursing homes, and care centers in which high-tech drug administration systems may not be used. Thus they need to be able to give medications safely and accurately, relying on their own ability to calculate the drug dosages accurately. **Chapter 4** includes the “need to know” content related to drug calculation and includes basic fractions, ratio and proportion, and dimensional analysis, a mathematical technique that is being adopted by many nursing programs for drug calculation. Intravenous drugs, oral drugs, parenteral drugs, and intravenous infusion calculation are presented in an organized, step-by-step manner. The application of topical, transdermal, mucous membrane, and eye and ear drugs is also presented with accompanying illustrations to help the student visualize the process while reading the material.

UNIT III

Drug classification groups provide essential information for student retention on select drug categories. Unit III focuses on content that has application to treatment purpose (i.e., anti-infective drugs), and chapters are associated with body systems, such as renal, urinary, and cardiovascular systems. By grouping drugs using the drug classification system, students quickly learn about individual drugs by understanding their drug class. The narrative content in the text focuses on major drug groups, and coverage of specific drugs appears in reference tables. A brand-new chapter covering drugs for cancer treatment has been added. In addition, special attention has been placed on drugs for reproductive health, the treatment of thyroid and adrenal problems and osteoporosis. All chapters have been updated in this edition to represent the latest clinical drug treatment information. Each drug class is presented in a consistent format with a separate Patient and Family Teaching section. Even though additional drug references can be used by students, the author team believes it is critical that students have a base knowledge of the potential dosage ranges for adult drugs to promote safe, effective practice. Thus drug dosage ranges are included in tables with each chapter in Unit III.

Chapter-ending NCLEX® Examination questions and Case Studies require the student to apply information gained from each chapter to address patient scenarios. Suggested answers to the questions and Case Studies are provided online in the TEACH Instructor Resources on Evolve at <http://evolve.elsevier.com/Visovsky/LPNpharmacology>.

TEACHING AND LEARNING PACKAGE FOR THE INSTRUCTOR

TEACH INSTRUCTOR RESOURCES

TEACH Instructor Resources on Evolve, available at <http://evolve.elsevier.com/Visovsky/LPNpharmacology>, provide a wealth of material to help you make your pharmacology instruction a success.

In addition to all of the Student Resources, the following are provided for faculty:

- The Exam View Test Bank has been completely updated with approximately 480 questions that feature Next-Generation NCLEX-style questions. Each question is coded for the correct answer, rationale, page reference, and cognitive level.
- TEACH Lesson Plans, based on textbook chapter Learning Objectives, serve as ready-made, modifiable lesson plans and a complete roadmap to link all parts of the educational package. These concise and straightforward lesson plans can be modified or combined to meet your particular scheduling and teaching needs.
- PowerPoint Presentations provide approximately 450 text slides for classroom or online presentations.
- Open-Book Quizzes for each chapter in the textbook help to ensure that your students are reading and comprehending their textbook reading assignments.
- An Image Collection includes all the illustrations and photos from the textbook.
- Suggestions for Working with Students Who Speak English as a Second Language help you promote the success of ESL learners.
- Answer Keys to the Critical Thinking Questions, Case Studies, and Study Guide activities and

exercises are available for your own use or for distribution to your students.

FOR THE STUDENT

Evolve Student Resources, available at <http://evolve.elsevier.com/Visovsky/LPNpharmacology>, include more than 400 interactive Review Questions for the NCLEX-PN® Examination, Video Clips, an Audio Glossary with pronunciations for more than 150 Key Terms, 12 Interactive Drug Dosage Calculators, newly proposed FDA Guidelines on Pregnancy and Lactation, and links to updated information on the Top 200 Prescription Drugs, a Bibliography, and a detailed Glossary.

A comprehensive Study Guide, available separately, includes Worksheets and Review Sheets with an enhanced focus on critical thinking, prioritizing, care of older adults, and cultural considerations. The exercises focus on promoting medication safety and prevention of drug errors.

In working with patients, the nursing student will quickly learn that giving medications is one of the most challenging parts of the nursing role. A nurse who develops the knowledge and skills needed to correctly give medications will be noticed and recognized with respect by both patients and colleagues in the health-care system. Both the responsibilities and the personal rewards are great.

Constance G. Visovsky, PhD, RN, ACNP, FAAN
Cheryl H. Zambroski, PhD, RN
Shirley Meier Hosler, RN, BSN, MSN

Acknowledgments

The eleventh edition of *Introduction to Clinical Pharmacology* represents a collaboration among three experienced nurse educators and clinicians who have taught pharmacology to all levels of nursing students. The 11th edition brings these authors back together with updated information, new drugs, and what the LPN/LVN needs to know to administer medications safely and monitor the patient for both expected and adverse effects. I remain grateful to my colleagues, Dr. Zambroski and Ms. Hosler, for their excellence and dedication to this work and for providing a textbook and test bank that will prove to be critical resources for the LPN/LVN student and faculty.

The author team remains extremely grateful to Dr. M. Linda Workman, our dear friend and mentor, who continues to provide her support and guidance to this author team. Lifetime mentors are few and far between, so we acknowledge her commitment and support.

The author team is grateful for the Elsevier editorial, production, marketing, and design staff. Special thanks to Brandi Graham, Senior Content Strategist, for her guidance to this author team; and to Andrew Schubert, Content Development Specialist, for his editorial guidance and support to keep the text production on track.

On behalf of the author team, I would like to express our eternal gratitude to our families and friends, who

supported our endeavors on this project and were our cheerleaders throughout the process. I would like to acknowledge the love and support of my husband, Bob Visovsky, who sustained me during this project. Thank you to my students, who inspire me every day to be a better teacher. Last, I would like to thank my God for presenting this opportunity to me and for providing the fortitude to take this textbook to completion.

**Constance (Connie) G. Visovsky,
PhD, RN, ACNP, FAAN**

Thank you to my terrific colleagues, Dr. Visovsky, Ms. Hosler, and Dr. Passmore, as well as to our students, who challenge and cheer us as we continue to learn each day. A special thank you to my husband, James, for his ongoing love and support during this project.

Cheryl H. Zambroski, PhD, RN

Thanks to every student who has shared a path with me along the way: I could never have achieved the process of learning how to write if you hadn't first taught me how to teach. To my colleagues, Connie, Cheryl, and Denise, you are the best of the best!

Shirley Meier Hosler, RN, BSN, MSN

About the Authors

CONSTANCE G. VISOVSKY, PHD, RN, ACNP, FAAN

Constance (Connie) G. Visovsky received her BS and MS degrees in nursing from the University of Rochester, Rochester, New York, and her PhD from Case Western Reserve University, Cleveland, Ohio. She is an acute care nurse practitioner, specializing in the treatment of patients with cancer. She is considered an expert in the area of chemotherapy-induced peripheral neuropathy and has grants and publications on this topic to her credit. Dr. Visovsky is an experienced nurse educator and scientist. She is currently Professor and the Lewis & Leona Hughes Endowed Chair in Nursing Science at the University of South Florida, College of Nursing.

CHERYL H. ZAMBROSKI, PHD, RN

Cheryl H. Zambroski received her diploma in nursing from Rockford Memorial Hospital School of Nursing, her BS and MS in Nursing from the University of Illinois, and her PhD in Nursing from the University of Kentucky. Her clinical experiences focused on adult health in areas that include emergency nursing, critical care, and medical-surgical nursing. She also worked as a clinical nurse specialist in cardiovascular and thoracic nursing. Her teaching career began at Jefferson

Community College in Louisville, Kentucky. She later taught a variety of courses in the undergraduate program and the clinical nurse specialist track at the University of Louisville. Currently, Dr. Zambroski teaches pharmacology, public health, and mental health nursing at the University of South Florida College of Nursing.

SHIRLEY MEIER HOSLER, RN, BSN, MSN

Shirley Meier Hosler received her AAS from Maria College in Albany, New York, later receiving her BSN from the University of New Mexico and MSN from the University of Illinois, Chicago. Shirley has more than 40 years of clinical, administrative, educational, and academic experience, having worked as a staff nurse, held numerous administrative nursing positions, and served on the faculty of colleges and universities. Her educational accomplishments include the development of online and classroom programs for nursing, emergency medical personnel, and paramedic professionals. Shirley has a broad base of expertise with specific concentration in the areas of prehospital medicine, adult medicine, and critical care. She has received numerous awards for her unique and innovative educational accomplishments.

To the Student

READING AND REVIEW TOOLS

- **Learning Outcomes** introduce the chapter topics.
- **Key Terms** are listed with page number references, and difficult medical, nursing, or scientific terms are accompanied by simple phonetic pronunciations. Key terms are considered essential to understanding the professional language and chapter content. Key terms are defined within the chapter, are in color the first time they appear in the narrative, and are briefly defined in the text, with complete definitions in the Glossary.
- Each chapter ends with a **Get Ready for the Next-Generation NCLEX® Examination!** section that might include (1) **Key Points** that reiterate the chapter outcomes and serve as a useful review of concepts, (2) an extensive set of **Review Questions for the NCLEX® Examination** with answers located on the Evolve site, (3) **Case Studies** with answers located on the Evolve site, and (4) **Drug Calculation Review Questions** with answers located on the Evolve site.
- A complete **Bibliography** section in the back of the text cites evidence-based information and provides resources for enhancing knowledge.

CHAPTER FEATURES

Procedures related to giving drugs are presented in a logical format with a defined purpose and relevant illustrations and are clearly defined and presented in a logical set of steps.



Memory Jogger boxes restate key points from anatomy, physiology, or pharmacology that are important for students to remember and serve as foundational information for giving and monitoring drug therapy. Basic principles of drug calculation are presented in easy-to-follow steps to reinforce learning.



Top Tip for Safety boxes identify the important knowledge that will aid students in giving particular drugs and will provide critical information and warnings of adverse effects of drugs that are important to patient safety.



Lifespan Considerations boxes draw attention to information that is especially important to remember when giving a specific drug to older adults, children, or pregnant/lactating women.



Safety Alerts indicate a particularly important factor to remember about a specific drug or drug class.

☛ **Canadian Drugs** indicated within the tables point out brands available only in Canada.



Video Clips located in the margins of the text indicate available relevant videos located on the Evolve site.



Bookmark This boxes list useful websites that provide important resources for all nurses.

Contents

UNIT I GENERAL PRINCIPLES, 1

1 Pharmacology and the Nursing Process in LPN Practice, 1

The LPN/VN'S Role and the Nursing Process, 1
Using the Clinical Judgment Model, 10

2 Legal, Regulatory, and Ethical Aspects of Drug Administration, 13

Introduction, 13
Regulation of Drug Administration, 14
The Drug Order, 18
Drug Administration Systems, 20
Drug Errors, 21
Protection of Healthcare Workers, 24

3 Principles of Pharmacology, 27

Introduction, 28
Drug Names, 28
Drug Attachment, 28
Basic Drug Processes, 29
Drug Actions, 32
Drug Therapy and Special Populations, 35
Drug Cards, 38

UNIT II PRINCIPLES OF DRUG ADMINISTRATION, 43

4 Drug Calculation: Preparing and Giving Drugs, 43

Introduction, 44
Calculating Drug Dosages, 44
General Principles of Drug Administration, 48
Enteral Drugs, 48
Parenteral Drugs, 51
Percutaneous Drugs, 64

UNIT III DRUG CATEGORIES, 73

5 Drugs for Bacterial Infections, 73

Infection, 73
Antibiotics, 75

6 Drugs for Tuberculosis, Fungal, and Parasitic Infections, 91

Tuberculosis, 91
Fungal Infections, 97
Parasitic Infections, 101

7 Drugs for Viral and Retroviral Infections, 108

Virus, 109
Antivirals, 109
COVID-19, 114
Retroviruses, 115
Antiretrovirals, 115

8 Drugs for Allergy and Respiratory Problems, 124

Allergy, 125
Drug Therapy for Allergy, 125
Asthma and Chronic Obstructive Pulmonary Disease, 132
Drug Therapy for Asthma and Chronic Obstructive Pulmonary Disease, 133
Mucolytics and Antitussives, 137

9 Drugs Affecting the Renal/Urinary and Cardiovascular Systems, 143

Diuretics, 144
Drugs for Benign Prostatic Hyperplasia, 148
Bladder Anesthetics, 148
Antihyperlipidemics, 150
Antihypertensive Drugs, 156
Drugs Used for Angina and Myocardial Infarction, 165

10 Drugs for Central Nervous System Problems, 176

Central Nervous System Functions, 177
Drugs for Parkinson's Disease, 178
Drugs for Alzheimer's Disease, 184
Drugs for Epilepsy, 188
Drugs for Multiple Sclerosis, 197
Drugs for Amyotrophic Lateral Sclerosis, 198
Drugs for Myasthenia Gravis, 200

11 Drugs for Mental Health, 204

Drug Therapy and Mental Illness, 205
Drugs for Sleep and Anxiety, 206
Antidepressants and Mood Stabilizers, 210
Antipsychotics, 222

12 Drugs for Analgesia and Anesthesia, 233

Pain, 234
Analgesic Drugs for Pain Management, 236
Miscellaneous Drugs for Pain Management, 244

13 Drugs for Inflammation, Arthritis, and Gout, 254

Inflammation Causes and Action, 254
Inflammation Management, 255
Gout, 266

14 Drugs for Gastrointestinal Problems, 271

The Digestive System, 272
Antiemetic Drugs, 273
Drugs for Peptic Ulcer Disease and
Gastroesophageal Reflux Disease, 280
Drugs for Constipation and Diarrhea, 285
Drugs for Irritable Bowel Syndrome, 292

15 Drugs for Immunization and Immunomodulation, 299

Overview of Immunity, 300
Vaccination, 302
Immunomodulating Therapy, 308

16 Drugs Affecting the Hematologic System, 314

Blood Clotting, 314
Anticoagulants, 315
Drugs for Iron Deficiency Anemia, 327

17 Drugs for Cancer Treatment, 331

Cancer, 331
Traditional Chemotherapy, 334
Hormone Therapy for Cancer Treatment, 341

18 Drugs for Reproductive Health, 345

Female Sex Hormones, 345
Male Sex Hormones, 350

19 Drugs for Thyroid and Adrenal Problems, 354

Overview of the Endocrine System, 354
Drugs for Thyroid Problems, 355
Drugs for Adrenal Gland Problems, 359

20 Drug Therapy for Diabetes, 364

Diabetes, 365
Drug Management for Diabetes Mellitus, 366

21 Drugs for Osteoporosis, 384

Overview of Osteoporosis, 384
Drugs for Osteoporosis, 386

22 Drugs for Eye and Ear Problems, 396

Ear Structure and Function, 396
Drugs to Manage Ear Problems, 397
Eye Structure and Function, 399
Glaucoma, 400

23 Over-the-Counter Drug Therapy, 413

Documenting Patient Healthcare Practices, 413
Over-the-Counter Drugs, 414
Herbal Products and Complementary and
Alternative Medicine, 416
Vitamins, 419
Minerals, 425

Answers to Clinical Judgment Questions, 430
Index, 443

Pharmacology and the Nursing Process in LPN Practice

<http://evolve.elsevier.com/Visovsky/LPNpharmacology>

Learning Outcomes

1. Explain how licensed practical or vocational nurses (LPNs/VNs) use the clinical problem-solving process (nursing process) in practicing safe drug administration.
2. Discuss the differences between subjective and objective data related to drug administration.
3. Describe the specific actions involved in using the nursing process to safely give drugs.
4. List specific nursing activities related to assessing, planning, implementing, and evaluating the patient's response to drugs.
5. Compare the steps of the nursing process to the skills needed in applying the clinical judgment model.
6. Describe each of the 9 *Rights of Drug Administration* as essential components of safe drug administration.

Key Terms

9 Rights of Drug Administration A series of nursing actions to protect the patient from drug error.

adverse effect A drug effect that is more severe than expected and has the potential to damage tissue or cause serious health problems. It may also be called *adverse effect*, *toxic effect*, or *toxicity* and usually requires an intervention by the prescriber.

assessment The first step of the nursing process; involves gathering information about the patient that will be used in planning care.

clinical judgment The observed outcome of critical thinking and decision making; an iterative process that uses nursing knowledge to observe and assess presenting situations, identify a prioritized client concern, and generate the best possible evidence-based solutions in order to deliver safe client care (National Council of State Boards of Nursing [NCSBN], 2019).

clinical problem-solving process (nursing process) A system to guide the nurse's work in a logical way; consists of five major steps: (1) assessment, (2) diagnosis, (3) planning, (4) implementation, and (5) evaluation.

contraindication Health-related reason for not giving a specific drug to a patient or a group of patients.

diagnosis A name (or label) for the patient's disease or condition.

evaluation The process of determining the right response by looking at what happens to the patient when the

nursing care plan is put into action. It is an appraisal of the treatment effectiveness.

expected side effects Unintended but not unusual effects of a drug that occur in many people taking the drug; the effects are usually mild and do not require the drug to be stopped.

healthcare setting Any setting in which the LPN/VN practices nursing.

identifiers Information used to reliably prove that an individual is the person for whom the drug treatment is intended; may include the person's full name, medical record identification number, birthdate, or telephone number.

implementation The act of carrying out the planned interventions.

objective data Information that can be seen, heard, felt, or measured by someone other than the patient.

planning Using information about the patient gathered in the nursing assessment to set short-term and long-term goals.

precaution Health-related reason that a drug may be given that requires more monitoring to avoid adverse events (precautions).

subjective data Reports of what the patient says he or she is feeling or thinking.

therapeutic effect The intended action of the drug, also known as a drug's beneficial outcome.

THE LPN/VN'S ROLE AND THE NURSING PROCESS

Licensed practical or vocational nurses (LPNs/VNs) play a vitally important role in providing nursing care

for patients and families across the lifespan. In fact, in December 2022 there were nearly 1,000,000 LPNs in the United States. The need for a well-educated LPN/

VN workforce is predicted to grow about 6% between 2021 and 2031, with projections of nearly 59,000 job openings annually over the decade. The factors that increase the demand for LPNs/VNs include an aging nursing workforce reaching retirement age, an aging population in general, and an increased number of people who are living with chronic and complex illnesses.

LPN/VN practice has shifted dramatically over the past decades, from the time when most graduates practiced in acute care settings (hospital-based care) until today, when graduates practice in a wide variety of long-term and community-based settings. LPNs/VNs practice in nursing homes, assisted living facilities, outpatient clinics, home health agencies, psychiatric/behavioral health facilities, hospices, rehabilitation centers, and other settings. No matter the setting, as an LPN/VN, you will share a responsibility with registered nurses (RNs) and other members of the health-care team to provide safe, quality, and cost-effective care.

Wherever you choose to practice, it is likely that drug administration will be a significant part of your role. A survey of new LPNs/VNs revealed that over half of their work hours were involved in providing care related to giving drugs and to monitoring patients receiving drugs, including parenteral therapies. These new nurses rated knowledge of “client safety” and “medication” as the most important for safe and effective professional practice regardless of the setting.

Before we begin discussing specific drugs, we review the client clinical problem-solving process as it

relates to drug administration. Although you may be familiar with the nursing process, we focus on how you will use it as you safely give drugs to patients in a variety of settings. To review, the **client problem-solving process (nursing process)** is a system that guides the nurse’s work in a logical way (Fig. 1.1). The nursing process consists of five major steps: (1) assessment, (2) diagnosis, (3) planning, (4) implementation, and (5) evaluation.

ASSESSMENT

Assessment is the first step in the nursing process, and it involves collecting important information (also called *data*) about the patient that will be used in planning care. Depending on the clinical setting, an RN is assigned as the staff member who must perform the initial full assessment for each patient. However, as an LPN/VN, you will often make vital contributions to this assessment and may even be asked to provide full nursing assessment via protocols. This step of the nursing process is important because it provides initial information as you begin to make a record for developing the plan of care.

The first part of assessment related to drug administration involves gathering information about the patient and the patient’s health condition before you give the drugs. When the patient is admitted to the **health-care setting** (any setting in which LPNs/VNs practice nursing), you can obtain that information by talking to the patient (or to his or her caregiver if necessary), checking the patient closely for signs and symptoms of illness, viewing past medical records, and reviewing




FIG. 1.1 The nursing process and examples of considerations associated with each step.

information the patient may have brought to the setting. Ask carefully about current health problems, a history of illnesses or surgeries, and drugs taken now and in the past (including over-the-counter [OTC] drugs and herbal or dietary supplements). This information is important for all team members and helps everyone to plan the patient's care. Information in the patient's history often directs the nurse and the physician to look for certain physical signs of illness that may be present.

Information you gather through assessment falls into two groups: subjective data and objective data. **Subjective data** are what the patient reports feeling and thinking. For example, if a patient reports feeling nauseated after taking a drug, you must accept the patient's word. You cannot see, hear, or feel the patient's nausea—that is why the data are subjective. A patient may report trouble breathing. Although you may observe rapid breathing, the degree of difficulty the patient feels cannot be measured. Information is subjective if you have to rely on the patient's words or if the symptoms cannot be felt by anyone other than the patient. In such cases you would report, "The patient states that. . . ." Other examples of subjective data that you may learn about from a patient interview include:

- The chief problem according to the patient (in the patient's own words)
- The patient's belief about what caused the problem
- The patient's description about what relieves the problem
- The patient's report of the severity of the problem

Objective data are data that can be seen, heard, felt, or measured by someone other than the patient. They include information obtained when the healthcare provider performs a physical examination or orders laboratory tests, x-rays, or other diagnostic tests. The RN or physician typically conducts a comprehensive physical assessment. As an LPN/VN, it is important for you to assess vital signs (respiratory rate, pulse, blood pressure, weight, height, temperature), physical findings based on careful observation, auscultation (listening with the stethoscope), and light palpation as appropriate for your clinical setting and your state's Nurse Practice Act. Other examples of objective data include:

- Presence of edema
- Quality of a cough
- Percentage of foods eaten at a meal
- Measures of intake and output

It is especially important to gather subjective and objective assessment data when the patient is first seen or on admission to the healthcare setting. This initial information can be used as a baseline for comparison as care progresses. In addition to the physical examination, it is important to gather a thorough patient history. Asking questions and listening carefully to the patient may be just as important as the physical examination or the results of laboratory tests. The LPN/VN is often with the patient, so he or she plays a very important role in continuing to

listen to what the patient says and reporting new information to the other healthcare team members.

The nurse may not always be the one gathering the subjective and objective data; however, the nurse and everyone else on the healthcare team should learn whatever information they can from the chart, the physician, the family, and other team members and use that information to plan the patient's care. Understanding the difference between subjective and objective information can help you in reporting, or charting, the information. Based on our previous example and because you do not objectively *see* nausea, if the patient reports nausea (subjective information), your charting should specify "The patient reports nausea" rather than "The patient is nauseated." However, if the patient vomits (objective information), you will record the time, color, and amount.

Much of your role in assessment may be reporting data you collect to the RN or to other members of the healthcare team. The primary role you play in assessing the patient is defined by your state's Nurse Practice Act, which lists what actions LPNs/VNs may and may not perform. Your role also may vary according to your healthcare setting's policies and procedures.

Factors to Consider in Assessing the Patient

Certain information is very helpful in planning the care of the patient who is receiving drug therapy. The baseline nursing assessment is conducted at the time of the patient's admission to the healthcare setting. An important part of the assessment is the patient's drug history. The patient is typically the best source; however, you may also include reports from caregivers (e.g., spouse, close relatives, friends) and past medical records (often in the electronic medical record [EMR]).

When asking about the patient's drug history, you will want to collect data in the following areas:

1. Symptoms, signs, or diseases that explain the patient's need for a drug (such as high blood glucose levels, high blood pressure, or pain)
2. The names and, when possible, dosages of all the drugs the patient is taking, including:
 - Prescription drugs (in this category, patients often forget to mention birth control pills and implanted birth control measures)
 - OTC drugs such as aspirin, vitamins, laxatives, cold and sinus preparations, and antacids
 - Alcohol or street drugs used for recreational purposes (e.g., marijuana, cocaine)
 - Alternative therapies such as herbal agents or nutritional supplements
3. Any problems that the patient has had with drug therapy, for example:
 - Allergies (include the name of the drug and the symptoms the patient experienced)
 - Diseases that may prohibit or limit use of some drugs (e.g., sickle cell disease, glucose-6-phosphate dehydrogenase deficiency, drug addiction, immune deficiencies)

Data collection in all of these areas is important because this information can help prevent drug interactions or complications of drug therapy. You will also use this information as you monitor the patient's response and any changes in patient condition or status that may influence drug therapy during the time the patient is in the healthcare setting. This will help you determine whether the drug is helping the patient.



Memory Jogger

Nursing assessment is the use of your observational, questioning, and listening skills to learn information about the patient that can be used to ensure that you are giving drugs safely.

DIAGNOSIS

After all data have been collected, the nurse and other healthcare team members must identify the patient problems. This is determined through data **diagnosis**. The RN interprets the assessment data to identify the patient problem. The physician uses select data to make the medical diagnoses. As an LPN/VN, your knowledge about the patient allows you to make a significant contribution to the overall plan of care, including the plan of care around drug administration. The following are examples of follow-up questions you will need to ask related to giving drugs:

- What are the major health-related problems of this patient?
- What drugs is the patient likely to require?
- What special knowledge or equipment is required in giving these drugs?
- What special concerns or cultural beliefs does the patient have?
- How much does this patient understand about the prescribed treatment and drugs?
- What factors affect the patient's ability for self-care?

Answers to these questions (1) help you contribute to the goals of nursing care, (2) affect strategies you will use to care for the patient, and (3) tell you what type of patient teaching will be needed. Answering these questions may be more challenging with children, older adults, or people whose language or culture is different from yours. However, just as a physician must have the correct diagnosis to prescribe the right treatment, finding the correct answers to these questions helps you to plan the best care for the patient.

PLANNING

Based on the data you help collect, the medical and nursing diagnoses are made, goals are set, and nursing care plans are written. As a member of the healthcare team, the LPN/VN will be able to assist with the **planning** step. The nursing care plan involves collaboration with nurses and patients or caregivers to determine the expected patient outcomes. Using the information gathered in the assessment about the patient's history, medical and social problems, risk factors, and how ill the patient may

be, goals are set on a short-term or a long-term basis. For example, the following short-term goal may be written: "The patient will describe pain at a level of 3 or below, on a scale of 0 to 10, 30 minutes after receiving a drug for pain." An example of a long-term goal is "The patient will demonstrate how to rotate injection sites for using his insulin pen by the time of discharge."



Memory Jogger

When collecting the drug history, be sure to include the patient's use of OTC drugs, such as herbal and dietary supplements, because they may interfere with prescription drugs.

Drug Orders and the Nursing Care Plan

Physicians, nurse practitioners, nurse midwives, nurse anesthetists, clinical nurse specialists, and physician assistants may write drug orders according to individual state laws. Large hospitals may have a staff *hospitalist*—a physician or nurse practitioner who practices in the hospital to oversee care for all patients. Teaching hospitals may employ resident doctors who are still in educational programs.

After a drug is ordered, the nurse must verify that the order is accurate. This is usually done by checking the drug administration record or EMR against the original order. You will need to learn and follow the procedures of the agency where you work when checking drugs and drug orders. In all care environments, you must carefully check each time you give a drug. This is essential to maintaining patient safety and minimizing the risk for errors or adverse effects.

The nurse must also apply knowledge about the drug to the specific drug order to determine whether the drug and the dose ordered seem to be correct. No part of the order or the reason for giving the drug should be unclear. (**Chapter 2** presents the information required for a clear and legal drug order.) Any questions about whether a drug is appropriate or safe for that patient must be answered before the drug is given. The EMR may alert the nurse if there is a problem with the order. However, good clinical judgment in carrying out the drug order is very important. If you determine that (1) any part of the order is incorrect or unclear, (2) the patient's condition would be made worse by the drug, (3) the person ordering the drug may not have had all the information needed about the patient when drug therapy was planned, or (4) there has been a change in the patient's condition and a question has arisen about whether the drug should be given, the drug should be *withheld* (i.e., not given) until the healthcare provider has been called and the question has been answered. If you think there is a problem with the drug order and the provider cannot be contacted or does not change the order under question, notify the charge nurse and the nursing supervisor as soon as possible. Most hospitals have clear policies about whom to contact, how to report this problem, and what to do next.

After you have the drug order and have decided to give the drug, include in your plan any patient problems that may increase the risk of issues related to the drug's side effects. For example, a patient who has poor vision may have a risk of falling in an unfamiliar hospital or nursing home setting. This is important if you are giving a diuretic and the patient needs to go to the bathroom frequently. You must plan ahead so that the patient can safely get to the bathroom. The importance of these problems may change over time as the patient's condition changes. Ongoing communication between nurses and the healthcare team is important to maintain safe, quality, and cost-effective patient care.

Factors to Consider in Planning to Give a Drug

Planning to give a drug involves four important steps:

1. Know the reason you are giving the patient the drug. In other words, what is this drug supposed to do for the patient?
2. Learn specific information about the drug, including:
 - The major action of the drug
 - Negative side effects that may develop
 - The usual dosage, route, and frequency
 - Situations in which the drug should not be given (**contraindications**)
 - Health-related reasons in which the drug should be given with greater consideration to avoid adverse events (**precautions**)
 - Main drug interactions (i.e., the possible influence of another drug given at the same time)
3. Plan for special storage requirements, procedures, techniques, or equipment needs, including:
 - Does the solution need to be shaken before it is given?
 - Should the drug be refrigerated?
 - Do you need a specific syringe (such as an insulin syringe)?
 - What special techniques are necessary for giving the drug, such as using an inhaler or not applying pressure to the site after giving certain injectable drugs?
4. Develop a teaching plan for the patient, including:
 - What the patient needs to know about the drug's action and side effects
 - What the patient needs to know to take the drug correctly
 - What the patient needs to report to the nurse or physician if there are any problems

As you develop your plan, be sure to use the data you gathered in the assessment and your knowledge about the drug. You will use this information as you prepare to implement your plan. Whether or not to give the drug will depend on your assessment, your knowledge, and your professional judgment.

Regarding drug orders, make certain that you understand each part of the drug order. Do not give the drug if you have a question about any part of the order.



Top Tip for Safety

CHECK THE EXPIRATION DATES INCLUDED ON THE DRUG LABELS: OUT WITH THE OLD!

Expired medications can be less effective and may adversely affect the patient's health.

The planning step of the nursing process is also the time to:

- Ensure that you have a place to gather the drugs that is quiet and free of interruption.
- Gather any special equipment you will need to give the drug (such as intravenous [IV] infusion pumps, alcohol wipes, or nebulizers).
- Review special procedures you will need to give the drug (such as the Z-track injection technique), to properly administer eye or ear drops, or to deliver a rectal suppository).

All of this information is documented in the nursing care plan in the paper chart or EMR so that other team members can see the plan.

IMPLEMENTATION

Implementation involves carrying out your plan of care as you safely give drugs to the patient. In planning the patient's care, you learned why each drug was ordered, the drug's actions, and how to safely give the drug. You will apply this knowledge during implementation of the plan. For example, if you are giving an angiotensin-converting enzyme inhibitor (see [Chapter 9](#)) to a patient with high blood pressure, you will need to check the patient's blood pressure before giving the drug. If you are planning to give the ordered penicillin antibiotic (see [Chapter 5](#)) and you notice that the patient has a red rash on his or her chest and arms, you would withhold the next dose of the drug until you have reported the rash to the healthcare provider, because it may indicate an allergic reaction. After you have carried out the plan, you will record in the patient's chart or EMR that you have given the drug.

The 9 Rights of Drug Administration

A major strategy for giving drugs to patients is the **9 Rights of Drug Administration**. The nurse must always keep in mind these nine commonly recognized rights of drug administration ([Box 1.1](#)). [Chapter 4](#) provides specific details about preparing and giving drugs.

You may have heard nurses in the clinical setting discuss the importance of the *five rights*, *six rights*, or *eight rights*. Over time, nursing has continued to emphasize those essential components of safe drug administration, and more rights have been added.

For our purposes, the nine rights ensure that you identify the *right patient* and give the *right drug* with the *right dose* using the *right route* at the *right time* for the *right reason*. Then you use the *right documentation* to record that the dose has been given. You then monitor the patient to assess the *right response*. The final right is that patients have the *right to refuse* the drug. You might

Box 1.1 The 9 Rights of Drug Administration

- The right patient—Use at least two identifiers.
- The right drug—Check the drug label at least three times.
- The right dose—Make sure that you use the right amount of the drug; double-check the dose.
- The right route—Never change the route of administration without an order.
- The right time—Make sure that the drug has not been given recently or should be given at a different time of day.
- The right reason—Does this make sense for this patient? Know your patient and the drug.
- The right documentation—Document after you have given the drug, never before.
- The right response—How is the patient responding to the drug? Does it work?
- The right to refuse—Patients have the right to refuse; ask the patient to clarify his or her reason, provide good patient teaching, and document.

wonder how you can remember nine things. A runner who really enjoyed racing in 15K races (9.3 miles) said that he liked them the best because he could divide them into three 5Ks (3.1 miles each) so it seemed easier. You can do the same with the nine rights.

This section reviews each right and explains the reason each is essential for safe, quality, and cost-effective care.

**Memory Jogger****THE 9 RIGHTS OF DRUG ADMINISTRATION (THREE AT A TIME)**

- Right patient, right drug, right dose
- Right route, right time, right reason
- Right documentation, right response, right to refuse

The Right Patient. Before you give any drug, make sure that you identify the right patient. The National Patient Safety Goals claim that the purpose of this approach is (1) to reliably identify the individual as the person for whom the treatment is intended and (2) to match the treatment to the person. To properly identify the patient, you use at least two identifiers. **Identifiers** are information that is used to reliably prove that an individual is the person for whom the drug treatment is intended. Identifiers may be the person's full name, medical record identification number, birthdate, or telephone number. These may be compared with the patient's identification bracelet (wristband) in appropriate situations. Healthcare agencies may specify the main identifiers to be used in the setting and/or use a barcode system to scan the drug to the wristband.

For patients who are alert and oriented, asking them their full name and birthdate and comparing the information with the medical record is a straightforward process. However, for those who are hard of hearing,



FIG. 1.2 Nurse checking the patient's wristband for identification. (From Hoffmann Wold, G. (2012). *Basic geriatric nursing* (5th ed.). Mosby.)

confused, very young or very old, or critically ill, be sure to compare the name, birthdate, or medical record number against the patient's wristband (Fig. 1.2). Best practice is to directly instruct the patient: "Tell me your full name." This is much safer than asking "Are you Joe Jones?" A patient who is confused may not understand the question and may say yes or no regardless of whether that is the correct name.

In the hospital setting, never give a drug to a patient who is not wearing a wristband. Some long-term care settings use photographs of patients to assist the nurse in identifying patients who might be confused. Never identify the patient solely by the room or bed number.

◆ **The Right Drug.** Each drug that is prescribed for the patient has a particular intended action. You will need to make sure that you give the right drug. Carefully compare the drug order with the drug label. Do not assume that the correct drug has been sent by the pharmacy.

Make sure that the drug is in the form prescribed because some drugs can come in multiple forms (e.g., tablets, capsules, syrup). Many drugs have names that look or sound almost the same as the names of other drugs; these are sometimes called *look-alike, sound-alike drugs*. The Institute for Safe Medication Practices (ISMP) has published a list of easily confused drug names (Table 1.1). The US Food and Drug Administration and ISMP also recommend the Tall Man lettering system to reduce confusion for look-alike drug names (Table 1.2). In this system, for example, Lamisil (brand name for an antifungal drug) is written as LamISIL. This helps highlight the "ISIL" part of the name so that the nurse does not confuse it with Lamictal (an antiseizure drug), written as LaMICTal. The Tall Man lettering system has been embraced by healthcare agencies as one more strategy to reduce drug errors.

Drugs may come individually wrapped in a unit-dose system package or as a prescription filled for one person; in rare cases, they may be taken from a unit's stock drugs. Sometimes the drug label includes a barcode that is scanned by a computer. However it is packaged, you must read the drug label at least three times.



Top Tip for Safety

Read the drug label three times!

1. Before taking the drug from the unit-dose cart or storage area
2. Before preparing or measuring the prescribed dose of drug
3. At the bedside before you give it to the patient

- ◆ **The Right Dose.** As an LPN/VN, you will want to make sure you are giving the right dose. The amount of drug to be given is typically ordered by the healthcare provider as a dose for the “average” patient. A patient who is older, who has experienced severe weight loss as a result of illness, or who is small or very obese may require changes in the usual dosages. Pediatric patients often have doses ordered based on how much they weigh. Geriatric or older adult patients may be very sensitive to many drugs and may require a change in dosage. If

the patient has poor liver or kidney function, changes in dosage may be necessary for the desired effect. The healthcare provider may order a specific dosage of the drug when treatment begins and may adjust the dose later based on changes in the patient's condition.

Giving the correct dose of a drug also requires that you use the proper equipment (e.g., insulin must be measured in an insulin syringe), the proper drug form (e.g., oral or rectal, water or oil based, scored tablets or coated capsules), and the proper concentration (e.g., 0.25% versus 0.5% solution for eye drops), and you must accurately calculate the right drug dose. For high-alert drugs (see Chapter 2), many healthcare settings have policies that require two nurses to check any drug dose that must be calculated—particularly for drugs such as narcotics, heparin, insulin, and IV drugs—to reduce the risk for error.

- ◆ **The Right Route.** Each drug must be given by the right route. The drug order must state how the drug is to be given (route of drug administration). The nurse must never change routes without obtaining a new order. Although many drugs may be given by different routes, the dose is often different for each route.

The oral route is the preferred route if the patient is oriented (i.e., awake and able to understand) and can swallow without choking. In some cases, faster delivery or a higher blood level of a drug is needed, and the drug may be given parenterally (e.g., subcutaneously or intravenously; see Chapter 4). Special precautions may be needed for drugs given through these routes (such as how fast they can be given or in what dosage). Review your drug references to ensure that you are giving the drug correctly.

For patients with breathing problems such as asthma, drugs that previously were given orally can now be given by an inhaler. This decreases the number of side effects by getting the drug directly to where it is needed: in the lungs. You will need to teach the patient techniques to achieve the greatest benefit from the inhaler. Other routes that you will see in practice are drugs given as eye drops, ear drops, topical agents,

Table 1.1 Examples from Institute for Safe Medication Practices Commonly Confused Drug Names

DRUG NAME ^a	CONFUSED DRUG NAME	CONFUSED DRUG NAME	CONFUSED DRUG NAME
Aciphex	Accupril	Diprivan	Ditropan
Adderall	Inderal	Flonase	Flovent
Allegra	Viagra	Lantus	Lente
Benadryl	benazepril	Lexapro	Loxitane
Bextra	Zetia	Microzide	Micronase
Captopril	carvedilol	Paxil	Plavix
Cozaar	Zocor	Pyridium	pyridoxine

^aBrand name drugs always start with a capital letter. Generic drug names always start with a lowercase letter.

Table 1.2 Examples from Institute for Safe Medication Practices List of Drug Names with Tall Man Letters

DRUG NAME WITH TALL MAN LETTERS ^a	CONFUSED DRUG NAME	DRUG NAME WITH TALL MAN LETTERS	CONFUSED DRUG NAME
busPIRone	buPROPion	SOLU-Medrol	Solu-CORTEF
chlorproMAZINE	chlorproPAMIDE	SandIMMUNE	SandoSTATIN
Glipizide	glyBURIDE	SEROquel	SINEquan
NIFEdipine	niCARDipine	ZyPREXA	ZyrTEC
cefTRIAxone	ceFAZolin	FLUoxetine	PARoxetine
KlonoPIN	cloNIDine	HumaLOG	HumuLIN
PriLOSEC	PROzac	hydroOXYzine	hydrALAZINE

^aBrand name drugs always start with a capital letter. Generic drugs typically start with lowercase letters. NOTE: Some generic drug names incorporate Tall Man letters. Generic drugs that start with Tall Man letters are identified with an asterisk.

or part of shampoos. The most important thing is that you give the right form of the drug for the right route.

◆ **The Right Time.** The drug order should say when and how often the drug is to be given. In many situations you will work with the RN (and/or pharmacist) to determine the right time. Most healthcare agencies have guidelines that specify what time drugs will be given when they are ordered (e.g., drugs given once a day are given at 9:00 a.m.). You must be familiar with your agency guidelines for general times of administration. Nevertheless, it will be important for you to report if the information suggests timing that conflicts with the usual guideline. For example, some statin drugs (given once a day) should be given before bedtime for best effect rather than in the morning. If you have any questions, make sure to notify the RN or the healthcare provider. It is always better to ask the question than to risk a mistake.

To be effective, many drugs must be given exactly on schedule, day and night, to keep the level of drug constant in the body. For example, if a patient is taking warfarin (an anticoagulant) to decrease the risk for blood clots, the drug must be given at the same time every day. Patients with infections should follow a very regular schedule to maintain a consistent level of antibiotics and decrease the risk for antibiotic resistance.

You may need to plan around other patient activities when you give drugs. A patient with a newly diagnosed infection may need to have a blood culture drawn *before* starting antibiotic therapy. If the patient is scheduled for an ultrasound, you may want to *hold* giving a diuretic in the early morning (i.e., wait until later) so that the patient does not experience urinary urgency while having the procedure. As you go through each chapter on drugs, you will learn more on this topic.

Drugs are usually given when there is the best chance for the body to absorb them and the least risk of side effects. Some drugs should be given when the patient's stomach is empty, and others should be given with food to prevent gastrointestinal side effects. Some drugs require that the patient not eat certain foods. Others do not mix well with alcohol. Antacids interfere with the absorption of a number of drugs and therefore need to be given 2 hours before or 2 hours after taking those drugs. When a patient is taking several drugs, check to ensure that the drugs do not interfere or interact with each other. (For example, some antibiotics can interfere with the action of birth control pills, and a sexually active woman taking both could become pregnant if she does not use another form of contraception.) Whenever you are giving a new drug or one you have never seen before, use your drug references to ensure that the timing is correct.

It is especially important to confirm the timing of one-time-only, as needed, and emergency drugs. *The nurse must be certain that no one else has already given the drug and that it is the appropriate time to give the drug.* Narcotics (opioids) are often ordered as “stat” (to be

Box 1.2 Factors to Consider in Giving a Drug at the Right Time

- Always confirm the last time the drug was given to avoid giving too much in too short a time period.
- Understand and follow the rules of your hospital regarding the times to give scheduled drugs.
- Check drug references for the best times to achieve the best drug absorption and to limit risks for interactions with other drugs.
- Give drugs at times ordered to help keep blood levels of the drug constant.
- Plan drug therapy while keeping in mind other diagnostic and laboratory testing that your patient may be experiencing.

given within a few minutes of the order) or “PRN” (as needed). Note on the patient's record as soon as possible that you have given a narcotic so that it is clear the patient has been given the drug. (For more information, see [Chapter 2](#).) **Box 1.2** lists the main factors to remember in giving a drug at the right time.

Even though it may be tempting if you are on a busy unit, never leave a drug at the bedside for the patient to take later. If the patient cannot take the drug when you bring it, you should return later with the drug. As a nurse, you must document the time the patient actually takes the drug. If you are not present when the patient takes the drug, you cannot document it.



Top Tip for Safety

MAKE CERTAIN THE PATIENT TAKES THE DRUG

Never leave a drug at the bedside for the patient to take later.

The Right Reason. All medications are prescribed for a clear purpose. As a LPN, you should have a good understanding of your patient's health problems. The prescribed drugs should make sense to you, even if you may not fully understand the specific disease pathophysiology. As you learn pharmacology, you will learn the basic uses of the specific drugs and this will help you apply what you have learned to your patients. For example, you may have a patient with a diagnosis of high blood pressure, you would expect the patient to have an antihypertensive drug in their plan of care. If you have a patient with decreased mobility, you would understand that a stool softener would be helpful in decreasing the risk of constipation. On the other hand, if you have a patient with a viral infection, and the patient is prescribed an antibiotic typically prescribed for a bacterial infection (for example ampicillin or doxycycline), you would double check with the charge nurse or other healthcare provider for the reason the patient is receiving this drug. If you have a patient who is having severe diarrhea, you would question why the patient is scheduled to receive a laxative (and you would hold the medication until you have talked to the

healthcare provider). Never be afraid to ask the charge nurse or healthcare provider to better understand why the patient is receiving the drug.

The Right Documentation. Increasingly, electronic health record and charting systems are being used in healthcare settings. Whether the nurse records giving the drug in a paper chart or uses an electronic chart, the basics are the same: You need to make the right documentation. Record the time, route, and site of administration (if parenteral) after you have given the drug. It is very important to record this right away; do not delay or wait until later. As a tool of communication, failure to record means that you did not give the drug. In an emergency or when a drug is used only once or twice, such a failure is very important.

The documentation must always list the drug given, the dose, and the time it was actually given, not the time it was supposed to be given. In some offices or clinics where immunizations are given, the policy may require that the lot number listed on the bottle be recorded in the patient's chart. Most charting systems include a place to record the patient's response to the drug. Any patient reports of problems or adverse effects must be noted in the chart and reported immediately to the head nurse and the physician.

It is vitally important that you *never record drugs that were not given or record them before they are given*. If a patient does not receive the drug for any reason, notify the nurse in charge or the healthcare provider according to the policies of your healthcare setting.

Following the rules of your healthcare setting and carefully following the rights of drug administration can reduce the risk for drug error. If an error is made, talking about it honestly and taking quick action to correct any damage are vitally important to protect the patient from harm. Acknowledging error is an essential, and ethical, part of nursing practice.

The Right Response. As every drug is prescribed for a right reason, you will want to determine if the patient is having the expected response. Your evaluation of the response, whether expected or unexpected, guides your next actions. For example, if a patient is prescribed an antihypertensive for a patient with high blood pressure, you will monitor the blood pressure to determine if the drugs have achieved the desired result. If, on the other hand, the patient experiences severe side effects from the drug, you will report to healthcare provider. Knowing the basic actions of the drug and the overall plan of care will help you to determine your actions.

The Right to Refuse. Patients do have the right to refuse drugs based on the principle of autonomy (right to self-determination). Although we recognize that patients can refuse (with rare exception; see the following paragraph), it is important to talk with patients regarding their reasons for refusal. In many cases, refusals are based on a lack of understanding about the purposes

of the drug, and talking about it gives you the opportunity to teach or clarify information about the drug. Another example is a patient who refuses a laxative because he or she has diarrhea—clearly a good reason! Whatever the reason, if the patient refuses after you have answered all of his or her questions, make sure to document the refusal in the medical record.

In some clinical areas (e.g., psychiatric units), patients may be a danger to themselves or to others. In those situations, know your state laws that allow emergency treatment orders. If there is any question, make sure to check with the RN or the healthcare provider.

EVALUATION

Evaluation is the process of determining the right response and looking at what happens to the patient when the nursing care plan is put into action. It is the appraisal of the treatment's effectiveness. Evaluation requires the nurse to watch for the patient's response to a drug, noting both expected and unexpected findings. For example, when antipyretics (i.e., drugs that reduce fever) are given, you will take the patient's temperature to determine whether the drug lowered the fever. When drugs are given to reduce blood pressure, you will do regular blood pressure checks. For drugs used to reduce pain, you will evaluate whether the drug reduced the patient's pain according to your agency's pain scale.

Evaluation of what happens when you give a drug helps the healthcare team decide whether to continue the same drug or make a change. Gathering such information is also a part of the continuing assessment of a patient during care that the nurse will record in the patient's chart. The nursing process may be seen as a circle (see Fig. 1.1). For example, the patient's temperature can be part of the evaluation step of the nursing process, but it may also be part of the assessment step when you notice that the patient's temperature remains elevated, indicating that the patient needs a different dose of the drug, a different drug altogether, or some additional treatment measures.



Top Tip for Safety

EVALUATE RESPONSE TO DRUG

It is important to watch the patient and look for any signs of improvement as well as any side effects, adverse effects, or allergic responses.

Factors to Consider in Evaluating Response to Drug

The nurse checks for three types of responses to drug therapy: therapeutic effects, expected side effects, and adverse effects.

Therapeutic effects are seen when the drug does what it was supposed to do. If you understand why the drug is being given (i.e., the therapeutic goal of the drug), you will be able to decide whether that goal is being met. For example, if the patient's blood glucose level is high and regular insulin is given, you should

see a lower blood glucose level when it is next checked. If the patient is constipated and takes a laxative, the patient should have a bowel movement.

Expected side effects are unintended but not unusual effects that occur in many people taking the drug; they are usually mild and do not require the drug to be stopped. One example of an expected side effect is the sleepiness that most patients feel when taking an opioid (narcotic) for pain. All drugs have side effects, but not all patients have every side effect listed for a single drug. Always document side effects. Side effects such as nausea or vomiting sometimes can be stopped by decreasing the dosage or by giving the drug with food. Telling the healthcare provider about the side effects helps him or her decide whether the patient should keep taking the drug or it should be stopped.

Adverse effects are seen when patients do not respond to their drugs in the way they should or develop new signs or symptoms. For example, a patient with pneumonia may be given penicillin. Although this antibiotic may be working to control the infection, the patient may develop shortness of breath, which could be an allergic reaction to the drug; in that case, the penicillin must be stopped. A patient taking an anticoagulant to prevent blood clots must be closely watched for signs of bleeding or bruising that would indicate the patient has taken too large a dose or has had a larger-than-expected response to the drug. *If you suspect a patient is having an adverse effect, report it to the RN or the healthcare provider immediately.* When serious adverse effects occur in response to a drug, the healthcare provider usually discontinues (stops) the drug.

The nurse is the healthcare worker who is most often with the patient and is therefore in an important position to notice the patient's response to drug therapy. Carefully and repeatedly evaluating the patient and documenting your findings in the patient's medical record is vitally important in the delivery of safe, quality, and cost-effective care.



Top Tip for Safety

Use the 9 Rights of Drug Administration each and every time you give a drug to a patient!

USING THE CLINICAL JUDGMENT MODEL

In 2023, the National Council of State Boards of Nursing (NCSBN) altered the format of the National Council Licensure Exam (NCLEX®) to include questions evaluating the new LPN/VN's ability in clinical decision making, also called **clinical judgment**. This requires you to be able to translate your nursing knowledge into clinical practice. The NCSBN definition of *clinical judgment* is “the observed outcome of critical thinking and decision making. This iterative process uses nursing knowledge to observe and assess presenting situations, identify a prioritized client concern, and

generate the best possible evidence-based solutions to deliver safe client care” (NCSBN, 2019, p. 1). This definition builds on and expands the nursing process and indicates that clinical judgment skills are not linear steps that are followed in a particular sequence.

After developing the definition of clinical judgment, the NCSBN developed a Clinical Judgment Measurement and Action Model. Six cognitive (thinking) skills—called *cognitive processes*—were identified as essential for nurses to make appropriate clinical judgment. These skills help nurses identify changes in a patient's clinical condition and know what actions to take and why. The six essential cognitive skills of clinical judgment are Recognize Cues, Analyze Cues, Prioritize Hypotheses, Generate Solutions, Take Action, and Evaluate Outcomes (NCSBN, 2019):

- **Recognize Cues**

Cues are elements of assessment data that provide important information for the nurse as a basis for making client decisions. In a clinical situation, the nurse determines which data are *relevant* (directly related to client outcomes or the priority of care) and of immediate concern to the nurse, or *irrelevant* (unrelated to client outcomes or priority of care). *For example, you recognize the specific lab values that are critical to whether or not you administer a certain medication. Of the patient's available lab work, you determine which values are relevant to the medication you are giving.*

- **Analyze Cues**

When using this skill, the nurse considers the context of the client's history and situation and interprets how the identified relevant cues relate to the client's condition. Data that support or contradict a particular cue in the client situation are determined, and potential complications are identified. *For example, once you are aware that a patient has a potassium level of 3.5 mEq/L, consider the effect of giving or withholding a furosemide diuretic for this patient.*

- **Prioritize Hypotheses**

For this skill, the nurse needs to examine all possibilities about what is occurring in the client situation. The urgency and risk for the client are considered for each possible health condition. The nurse determines which client conditions are the *most likely* and *most serious*, and why. *For your patient with the potassium level of 3.5 mEq/L, there is a risk of heart rhythm disturbances if the furosemide diuretic is given and the potassium drops too low. Although the patient may need diuretics for the heart failure, it is a priority to make sure that it can be given safely.*

- **Generate Solutions**

To generate solutions, the nurse first identifies expected client outcomes. Using the prioritized hypotheses, the nurse then plans specific actions that may achieve the desirable outcomes. Actual or potential evidence-based actions that should be *avoided* or are *contraindicated* are also considered because some actions could be harmful for the client in the given situation. *For the considered patient, holding the furosemide until plans are made to supplement oral potassium can prevent hypokalemia and allow administration of the diuretic.*

- **Take Action**

Using this skill, the nurse decides which nursing actions will address the highest priorities of care and determines in what priority these actions will be implemented. Actions can include, but are not limited to, additional assessment, health teaching, documentation, requested primary healthcare provider orders, performance of nursing skills, and consultation with healthcare team members. *Recognizing the problem, you contact the healthcare provider with the information and receive an order for 20 mEq KCl orally to be given with the furosemide.*

- **Evaluate Outcomes**

After implementing the best evidence-based nursing action, the nurse evaluates the actual client outcomes in the situation and compares them to expected outcomes. The nurse then decides if the selected nursing actions were effective, ineffective, or made no difference in how the client is progressing. *The patient*

avoids irregular heart rate, lung sounds are clear, and the patient has no peripheral edema.

As mentioned, the six clinical judgment skills build on and expand the nursing process. The following table shows a comparison of the steps of the nursing process and the essential cognitive skills needed for sound clinical judgment.

STEPS OF THE NURSING PROCESS	COGNITIVE SKILLS FOR CLINICAL JUDGMENT
Assessment	Recognize Cues
Diagnosis	Analyze Cues
Diagnosis	Prioritize Hypotheses
Planning	Generate Solutions
Implementation	Take Action
Evaluation	Evaluate Outcomes

Get Ready for the Next-Generation NCLEX® Examination!

Key Points

- Use the 9 Rights each and every time you give a drug to a patient.
- Nursing assessment is using your observational, questioning, and listening skills to learn information about the patient that can be used to ensure that you are safely giving drugs.
- When assessing a patient, always ask carefully about current health problems, history of illnesses, history of surgeries, and drugs taken (including OTC and herbal drugs), both now and in the past.
- Always know why you are giving the patient the drug.
- Check the label of each drug you are giving three times to ensure that it is the right drug.
- Do not give a drug that was made for one route by any other route.
- When giving a one-time-only drug, take extra precautions to make certain that it has not already been given by someone else.
- Never record drugs that were not given or record them before they are given.
- Always use two unique patient identifiers when giving a patient a drug.
- If a patient refuses to take a drug, clarify the patient's reason and make sure to document the refusal.
- All drugs have side effects, but not all patients have every side effect listed for any single drug.
- Any questions about whether a drug is appropriate or safe for that patient *must* be answered before the drug is given.
- If you suspect a patient is having an adverse effect, report it immediately to the RN or the healthcare provider.
- Never leave a drug at the bedside for the patient to take later.
- In the hospital, never give a drug to a patient who is not wearing an identification band.

Clinical Judgment and Next-Generation NCLEX® Examination-Style Questions

1. Which of the following is considered a therapeutic effect?
 1. Tachypnea
 2. Decreased nausea
 3. Edema of left foot
 4. Irregular heart rate
2. Which of the following examples would be considered objective data? **Select all or any that apply.**
 1. "I have pain in my chest."
 2. Blood pressure is 140/70.
 3. Skin is warm and dry.
 4. "I had an appointment last week with my doctor."
 5. Child's mother states, "His temperature was 102 degrees before we came to the hospital."
 6. Weight gain of 3 pounds in 4 days.
 7. Patient states she has trouble breathing or "catching" her breath.
3. Which of the following would be considered examples of the 9 Rights? **Select all or any that apply.**
 1. Right patient
 2. Right time
 3. Right room number
 4. Right to refuse
 5. Right documentation
 6. Right reason

4. Which of the following examples would be considered a contraindication?
1. Giving a drug for pain to a patient who has a fractured left ankle
 2. Giving a drug that causes birth defects to a patient who is 8 weeks pregnant
 3. Giving a drug that may cause dizziness to a patient with high blood pressure
 4. Giving a drug that may cause an increase in heart rate to a patient who has asthma
5. The LPN/VN is giving a patient her morning drugs due at 9:00 a.m. After you have already prepared the drug, the patient states, "No, I don't want that pill today." What is your best first action?
1. Tell the patient she has to take the drug because it was ordered by the doctor.
 2. Ask the patient to tell you her reason for not taking the drug.
 3. Teach the patient why she needs it and give the drug.
 4. Ask the patient if she has any questions about the drug.
6. A patient recently began taking an antibiotic for a wound infection and presents for a follow-up appointment. The office nurse reviews the patient's temperature and checks for wound drainage. Which stage of the nursing process corresponds to this review?
1. Assessment
 2. Diagnosis
 3. Planning
 4. Intervention
 5. Evaluation
7. For which patient should the LPN/VN contact the healthcare provider to obtain a new order for an alternative route of drug administration?
1. The patient who is a newly diagnosed diabetic
 2. The patient who must take the drug with food
 3. The patient who is experiencing nausea and vomiting
 4. The patient who is receiving a drug for pain after surgery
8. Based on the following data, the risk for a drug error to be made is highest in which patient?
1. An 87-year-old patient who is drowsy after receiving pain medication
 2. A 14-year-old patient who is in traction after experiencing a broken leg
 3. A 65-year-old patient who has just undergone a knee replacement
 4. A 24-year-old pregnant patient who speaks both Spanish and English fluently

9. What is the best way to check that you are giving the drug to the right patient?
1. Ask the patient's name.
 2. Compare the patient with the room number.
 3. Check the patient's wristband.
 4. Check two unique patient identifiers.
10. The LPN is caring for a patient transferred from the acute care setting to a skilled nursing facility for rehabilitation following diagnosis of post-COVID syndrome. The patient describes generalized weakness, fatigue, difficulty sleeping, anxiety, and shortness of breath with minor activity. While in the hospital, the patient had intermittent episodes of confusion but was oriented to person, place, and time at admission. Admission vital signs were BP 160/70, HR 78, RR 18. The patient is to receive an oral blood pressure tablet.

For each potential step to give the drug, place an X in the box to indicate whether the action would be *Essential* (appropriate or necessary), *Non-Essential* (makes no difference or not necessary), or *Contraindicated* (could be harmful).

NURSING ACTIONS FOR DRUG ADMINISTRATION	ESSENTIAL	NON-ESSENTIAL	CONTRA-INDICATED
Assess the patient's mental status.			
Use two patient identifiers before giving the drug.			
Check the patient's blood sugar.			
Lay the patient flat in bed.			
Check the patient's blood pressure before administration of the drug.			
Document that the drug has been given following administration.			
Teach the patient that drugs for blood pressure may cause dizziness.			
Get the patient up in the chair before giving her the medication.			

Legal, Regulatory, and Ethical Aspects of Drug Administration

2

<http://evolve.elsevier.com/Visovsky/LPNpharmacology/>

Learning Outcomes

1. Describe the legal, regulatory, and ethical responsibilities of a nurse for drug administration.
2. Explain the meaning of controlled substances (scheduled drugs) and why drugs are placed in this category.
3. Describe the legal responsibilities for managing controlled substances.
4. List the information required for a legal drug order or prescription.
5. Describe the four different types of drug orders.
6. List what you need to do if you make a drug error.

Key Terms

as needed or PRN drug order An order for a drug to be given as needed based on a nurse's judgment about safety and patient need.

black box warning A special designation from the FDA indicating that the drug has a higher-than-normal risk for causing serious or life-threatening problems in addition to its positive benefits for some people.

controlled substances Drugs that are highly regulated because they are commonly abused; also known as *scheduled drugs*.

emergency or stat drug order A one-time drug order to be given immediately.

high-alert drugs Drugs that have the potential to cause significant harm to patients.

legal responsibility The nurse's authority as defined by the Nurse Practice Act in each state. It involves the nurse's judgment and actions while performing professional duties. All nurses must know what is legal in regard to drugs in the state in which they practice.

Nurse Practice Act The state law that licenses LPNs/VNs, registered nurses, nurse anesthetists, nurse practitioners, and nurse midwives. It describes the minimal educational preparation and professional requirements needed to perform specific functions, including drug administration, to protect the public safety.

over-the-counter (OTC) drugs Category of drugs identified by federal legislation that pose a low risk to patients; they may be purchased without a prescription, have a low risk for abuse, and are safe when directions are followed.

physical dependence The physical symptoms that occur with drug withdrawal (e.g., shaking, increased heart rate, pain, confusion, seizures).

prescription drugs Category of drugs regulated by federal legislation because they are dangerous, and their use must be controlled; they may be purchased only when prescribed. Examples are antibiotics and oral birth control pills.

prescriptive authority The authority designated by an individual state that determines who is legally permitted to write an order or prescription for drugs.

professional responsibility The obligation of nurses to act appropriately, ethically, and to the best of their ability as healthcare providers.

psychological dependence Feeling of anxiety, stress, or tension when a patient does not have access to a medication.

single drug order A one-time order to be given at a specified time.

standing drug order A drug order that indicates the drug is to be given until discontinued or for a certain number of doses.

INTRODUCTION

As a nurse you must understand the legal, ethical, and professional responsibilities associated with drug administration, as your decisions can result in consequences for the patient. The nurse's responsibilities include a thorough understanding of the drugs to be given, drug delivery systems, the accurate interpretation of drug orders, safe medication administration

practices, and the nursing process as it relates to drug therapy. Failure of the nurse to carry out these responsibilities can result in serious drug errors and patient harm. There are also ethical issues that may occur while giving drugs to patients. For example, in assisted living or nursing home facilities, it is a common practice to mix drugs with food or drink, mainly to help patients swallow their prescribed drugs more

easily. Before you decide to give drugs mixed in food or drink, you should consider several things: You have an ethical responsibility to inform the patient's care provider, the patient, and the family that you will be giving the drugs in this manner. Failure to inform the provider, patient, or family of this practice is considered *covert drug administration*, which, although not illegal, is not considered a best practice in drug administration. The mixing of drugs with food or drink must be documented in the patient's care plan and on the drug administration chart to address the legal aspects of this practice. Additionally, certain foods or drinks, such as grapefruit juice, should not be taken with certain drugs because this practice may influence the effect of that drug. It is important to check your drug handbook before mixing drugs with food or drink.

It also is important to know which types of drugs cannot be crushed or have the capsule opened. For example, a 325-mg, enteric-coated aspirin pill may be difficult for some patients to swallow, but crushing the drug affects the speed at which it is absorbed and increases the chance that the patient will develop a stomach ulcer. Some drugs have a coating that slows the release of the drug. Crushing capsules and tablets releases all of the drug at once, instead of slowly over time, and can result in accidental overdose. The Institute for Safe Medication Practices (ISMP) has published a "do not crush" list that can be used for reference: <http://www.ismp.org/tools/donotcrush.pdf>.

Another important legal and ethical issue facing nurses is known as *drug diversion*. Drug diversion is defined as the illegal transfer of regulated drugs (e.g., narcotics) from the patient for whom they were prescribed to another person (e.g., a nurse), for use by themselves or others. When a nurse diverts a prescribed drug, it can result in significant threats to patient safety and is a liability for the healthcare organization that employs the nurse. The American Nurses Association (ANA) has defined an *impaired nurse* as one who cannot meet the professional code of ethics because of excessive use of alcohol or drugs. When drug diversion is suspected, the organization is required to launch a full-scale investigation. The nurse involved will most likely face disciplinary charges that will include treatment resources for the nurse with drug or alcohol addiction and may include suspension or permanent loss of the nurse's license.

Nurse leaders have a legal and ethical obligation to protect patients and the profession from impaired nurses. Some behaviors that may signal a drug or alcohol dependency problem in a nurse include increased absences, lateness to work, unexplained disappearance from the assigned unit, and decreased alertness. Drug diversion should also be suspected if patients continually report pain despite appropriate drug treatment and if inaccurate counts are noted.

REGULATION OF DRUG ADMINISTRATION

Nurses who give drugs are required to follow three levels of rules:

1. Federal laws, which describe rules that control how certain drugs may be given
2. State laws and regulations, or rules, which specify who may prescribe, dispense (give a supply), or give drugs and the process to be used
3. Individual hospital or agency rules, which may specify other guidelines or policies regarding how and when drugs are given and the records that must be kept recording drug treatment

FEDERAL LAWS

Congress is responsible for passing laws that make drugs as safe as possible for patients to take and to create measures that ensure that drugs do what they claim to do (effectiveness). Congress created the US Food and Drug Administration (FDA) to monitor or watch over the testing, approval, and marketing of new drugs. These regulations are very strict, and US drugs are some of the purest and most protected drugs in the world. Many laws have been passed to control drugs that might easily be abused and are dangerous. These laws define the three drug categories in the United States:

1. **Controlled substances**, which include opioids (narcotics) and some sedatives or tranquilizers
2. **Prescription drugs** such as antibiotics and oral contraceptives
3. **Over-the-counter (OTC) drugs** that are available without a prescription

Substance Abuse and Misuse

It is important for nurses to understand and be able to distinguish the differences between substance (drug) abuse and misuse. Substance abuse or *drug abuse* is defined as harmful or hazardous use of psychoactive substances, including alcohol and illicit drugs. The danger of psychoactive substances is that they pose a significant risk for addiction. However, *drug misuse* is defined as the use of illegal drugs and the inappropriate use of legal substances, such as alcohol and tobacco. It is important to note that *drug misuse* also applies to prescription medications and over-the-counter medications. In essence, drug misuse means the patient is using the drug in a way other than what was intended. Substance use disorders occur when the chronic use of alcohol and/or drugs causes significant health problems, disability, and failure to meet major responsibilities at work, school, or home.

Controlled Substances

Regulations are written for controlled substances because they are most often abused by patients and the general public. The Controlled Substances Act of 1970 classified such drugs into five schedules, and they became known as *scheduled drugs*. Each schedule rates

the likelihood that the drugs in that category will be abused, causing dependency or addiction.

For example, Schedule I drugs, such as heroin, have no medical use and are considered highly addictive. At the other end of the schedules are Schedule V drugs, such as cough medicine with low-dose codeine, which have a low potential for abuse. The degree of control, the recordkeeping required, the order forms, and other regulations are different for each of these five classes. Table 2.1 describes the five drug schedules, with examples of drugs in each category. Drugs are sometimes moved from one class to another if it becomes clear they are being abused by the public. Many states have approved the medical use of marijuana for the treatment of certain conditions, mostly in cases of terminal illness.



Memory Jogger

- **Physical dependence** refers to the *physical symptoms* occurring during drug withdrawal. Symptoms such as shaking, increased heart rate, pain, confusion, seizures, and other troubling symptoms can occur.
- **Psychological dependence**, or addiction, is a *mental desire* associated with taking certain substances, such as cocaine or alcohol. Symptoms of mental dependence such as anxiety, anger, or depression can occur with psychological dependence.

Federal and state laws make it a crime for anyone to have controlled substances without a prescription. Each state has a practice act that lists which health-care providers may dispense or write prescriptions for controlled substances. Almost all states have programs for prescription monitoring of controlled substances received by patients from several different providers to prevent prescription drug abuse. Physicians, dentists, nurse practitioners, physician assistants, and sometimes nurse midwives may write prescriptions for controlled substances. Pharmacists dispense the drugs according to the provider's orders. Licensed practical nurses (LPNs) or licensed vocational nurses (LVNs) may give controlled substances to a patient only if the state board of nursing permits it in its scope of practice, and they must be under the direction of a healthcare provider who is licensed to prescribe these drugs.

Legal Responsibilities in Drug Administration

LPNs/VNs work in many different settings. Some settings may have high levels of technology for securing controlled substances, and others may use a double-lock system. Each state and healthcare agency has laws and policies that cover ordering, receiving, storing, and recordkeeping of controlled substances.

Table 2.1 Classification of Controlled Substances in the United States

SCHEDULE	DESCRIPTION	EXAMPLES
I	High potential for abuse No accepted medical use in treatment Lack of accepted safety for use of the drug or other substance under medical supervision	More than 80 drugs or substances, of which the following are best known: alpha-acetylmethadol, gamma-hydroxybutyric acid (GHB), heroin, lysergic acid diethylamide (LSD), marijuana, mescaline, peyote, methaqualone (Quaalude)
II	High potential for abuse Currently accepted use for treatment Abuse may lead to severe psychological dependence or physical dependence	More than 30 drugs or substances, of which the following are best known: amphetamines, cocaine, codeine, fentanyl, hydromorphone (Dilaudid), meperidine (Demerol), methadone, methylphenidate (Ritalin), morphine, oxycodone (Percodan), pentobarbital, secobarbital
III	Potential for abuse less than the drugs or substances in Schedules I and II Currently accepted medical use for treatment Abuse may lead to moderate or low physical dependence or high psychological dependence	Most drugs are compounds containing some small amounts of the drugs from Schedule II along with acetaminophen or aspirin, such as acetaminophen with codeine (Tylenol #3 or #4) and aspirin/butalbital/caffeine (Fiorinal) Other drugs include anabolic steroids such as testosterone preparations and sodium oxybate (Xyrem), a drug that contains GHB for use with the sleep disorder narcolepsy
IV	Low potential for abuse relative to the drugs or substances in Schedule III Currently accepted medical use for treatment Abuse may lead to limited physical dependence or psychological dependence relative to the drugs or substances in Schedule III	Includes diet drugs containing propionic acid Other well-known drugs include benzodiazepines such as lorazepam (Ativan), flurazepam (Dalmane), diazepam (Valium), midazolam (Versed), and alprazolam (Xanax) and the following: chloral hydrate, paraldehyde, pentazocine (Talwin), phenobarbital
V	Low potential for abuse relative to the drugs or substances in Schedule IV Currently accepted medical use Abuse may lead to limited physical dependence or psychological dependence relative to the drugs or substances in Schedule IV	Includes cough preparations containing small amounts of codeine and drugs for diarrhea that also contain small amounts of opioids, such as diphenoxylate with atropine (Lomotil)

From U.S. Drug Enforcement Administration (DEA), Title 21 U.S.C. Section 812.

Opioids (narcotics) are scheduled drugs, and all of them must be counted during every shift. Records must be kept for every dose given. Agency policy determines which nurses will be held responsible for handing over the control of controlled substances from one shift to the next and for counting and securing controlled substances. All controlled substances that are ordered for a patient but not used during the hospital stay are sent back to the pharmacy when the patient is discharged.

Nurses may never borrow a drug ordered for one patient to use for another patient, and they may never use these drugs for themselves. In a time when drug abuse is so common, the nurse who has responsibility for the controlled substances must remain alert. With about 8% to 15% of healthcare professionals having a history of substance abuse, there is a risk for drug diversion. Some potential clues for identifying drug diversion include a pattern of drugs frequently being “dropped” or “spilled” or unrelieved pain in patients who received large or more frequent doses of drugs. As a nurse, you must know the federal, state, and agency rules about giving any type of drug, including controlled substances. The rules that govern controlled substances are very clear and very strict. If you violate the controlled substance laws, you may be punished by a fine, a prison sentence, or both. Nurses with drug abuse problems can temporarily or permanently lose their license to practice. Nurses have an ethical and a **legal responsibility** to report suspected drug diversion. In most states, the state board of nursing has a program to help nurses with substance abuse that affects their ability to carry out their nursing duties.

Distribution of Controlled Substances and Drugs.

Federal and state laws and institutional policies are clear about how controlled substances are handled in hospitals and other agencies. The goal of all regulations and policies is to verify and account for all controlled substances. In some cases, a paper-based system may be used. When controlled substances, particularly opioids (narcotics), are ordered from the pharmacy, they come in single-dose units or prefilled syringes and are attached to a special inventory count sheet. The nurse receiving the order from the pharmacy must inspect the drug and return to the pharmacy a signed record stating that all of the drug ordered was received and correct as verified by two nurses. As each drug is used, it must be accounted for on the inventory sheet by the nurse giving the drug. The use of opioids (narcotics) is carefully monitored on the unit. Controlled substances are stored in a special double-locked cabinet. The keys to this cabinet are kept in a locked box with code access or carried by the charge nurse or a nurse responsible for accounting for opioids (narcotics) on the unit. The nurses who are responsible for the narcotics key has the legal responsibility for overseeing the use and recording of

all opioids during a shift, regardless of whether he or she personally gives the drugs to the patients.

There are also automated drug dispensing systems such as the Pyxis. These systems may include dispensing of opioids, routinely stocked drugs, and drugs specifically prescribed for individual patients. Nurses withdraw drugs by giving a password or fingerprint instead of using a key to open a locked cabinet. One issue to note is that drug orders can be overridden in the Pyxis under specific circumstances, such as when an emergency verbal order is received from the provider. A record is kept of what is ordered and used for patients in these circumstances, but overriding drug orders can result in critical drug errors if not done carefully.

When controlled substances are ordered for a patient, the nurse who will give the drug first checks the order, dosage, and last time the drug was given before obtaining the controlled substance. All nurses giving controlled substances must officially sign out all the controlled drugs given during the shift. The agency’s inventory report is completed before the drug is removed from the cabinet or Pyxis. This report may be in the form of a written document, or a patient’s barcode may be used instead. The report form should include the patient’s name, date, drug, dosage, and signature of the nurse giving the drug. A follow-up note about the patient’s response to the drug may also be required. If a dose is ordered that is smaller than that provided (so that some of the drug must be discarded) or the drug is accidentally dropped, contaminated, spilled, or otherwise made unusable and unreturnable, *two nurses* must sign the inventory report and describe the situation. Institutional policy may require additional actions.

If a key or keys are used to access controlled substances in a cabinet, at the end of each shift the responsibility for the keys is transferred to another authorized nurse from the new shift. Keys or electronic access to controlled substances are never given to physicians or any other unauthorized healthcare worker. The contents of the locked cabinet are counted together by one nurse from each shift. The numbers of each ampule, tablet, and prefilled syringe in the cabinet must match the numbers listed on the inventory report form. Sealed packages are kept sealed. Opened drug packages must each be inspected and counted. Prefilled syringes must be examined to make sure they all have the same color, the same fluid levels, and the same amounts of air within them. Both nurses must sign the inventory report, officially stating that the records and inventory are accurate at that time.

Occasionally, the inventory and the written report do not agree. Any disagreement between the number of remaining doses and the number listed in the inventory report must be explained. All nurses who have access to the cabinet keys or the locked Pyxis must be asked about the controlled substances they have given.

Steps must be retraced to see if someone forgot to record any drug. Patient charts can also be checked to see if a controlled substance was given that was not signed for on the inventory report. If errors in the report cannot be found, both the pharmacy and the nursing service office must be notified, and an investigation is opened to determine if drug diversion has occurred. Depending on the type and magnitude of the issue, the institution or agency administrator and security police also may be contacted.



Top Tip for Safety

CONTROLLED SUBSTANCES

Verify all orders for controlled substances. Only authorized nurses can be responsible for access to and delivery of controlled substances, and for the LPN/LVN, this authority may differ between states and provinces. Follow all regulatory policies and procedures for safety and security of controlled substances. Report any suspicious findings that may point to possible drug diversion.

Prescription Drugs

In the United States, the safety and effectiveness of prescription drugs are regulated by the Federal Prescription Drug Marketing Act (1987), and it is the responsibility of the Food and Drug Administration (FDA) to decide which drugs will require a prescription to be obtained. This regulation is in place to prevent prescription drug misuse and abuse. The ability to write prescriptions is provided to only a few health-care professionals (e.g., physicians, dentists, nurse practitioners, physician assistants).

Misuse or abuse of prescription drugs can lead to adverse drug events, including those caused by dangerous drug interactions. The most commonly abused prescription drugs include narcotics (opioids) and drugs given for sleep or anxiety disorders.

The Omnibus Budget Reconciliation Acts of 1989, 1990, and 1991 placed further controls on drugs for Medicare or older adult patients. According to one study, as many as 15% of older adults are at risk for potentially major drug–drug interactions. Older patients are at high risk for problems with prescription drugs. They may not take the drug properly because of poor eyesight, memory, or coordination; they may take many drugs that interact with each other; or they may have chronic diseases that interfere with how the drug works.

Medicare Plan D provides coverage of some types of drugs for those who pay for this insurance option. More and more, insurance and government groups that pay for drugs limit the types and numbers of drugs that may be ordered to those on a “preferred” drug list. The preferred drug list may require the use of cheaper generic drugs to control costs because new or brand-name drugs usually are more expensive. Many drugs are not FDA approved as safe and effective for

children or pregnant women. Prescription drugs make up most of the drugs given to patients in assisted living centers, nursing homes, or hospitals. Prescription drugs are carefully tested for safety and effectiveness before they are put on the market. However, even though much may be known about a particular drug, each patient can have different reactions to it. You must know the expected and adverse effects of drugs given to your patients and watch for signs that the drug is working the way it should. Any adverse reactions that may develop must be reported to the ordering provider. Patients often take several drugs at the same time, and the interaction among the drugs may make it hard to tell how each drug affects the patient, making your nursing knowledge of these drugs a critical part of safe nursing practice.

Over-the-Counter Drugs

The FDA has also found that many drugs are safe enough not to need a prescription. These drugs are known as over-the-counter (OTC) drugs. OTC drugs are used to treat many common minor problems, such as colds, allergies, headaches, minor burns, constipation, or upset stomach. These drugs may be purchased easily at a drugstore or pharmacy. They are often the first thing patients try before they go to the doctor. Although OTC drugs are widely available, they are not without some risk. Like all drugs, some OTC drugs may produce adverse effects in some patients. There is also the possibility of adverse drug or food interactions or harm caused by excessive doses. Patients should be taught to read the drug facts label that is included with all OTC products and to consult with their pharmacist or other healthcare provider if they have additional questions concerning OTC drug use.

Accidental overdoses of common cold drugs in children have occurred because of confusion by parents about the correct dosage to give, and these drugs are no longer recommended for use in pediatric patients. Studies have shown that 40% of parents give their children incorrect dosages of liquid drugs. Cold and allergy products that contain pseudoephedrine and can be used to make illegal drugs are now stored behind the pharmacy counter and are sold in limited quantities. OTC drugs that are given in assisted living centers, nursing homes, and hospitals require a legal prescriber’s order before they are given. Without an order in these settings, patients cannot take even the OTC drugs they brought with them.

CANADIAN DRUG LEGISLATION

The Health Products and Food Branch of Canada’s Department of National Health and Welfare is like the FDA of the US Department of Health and Human Services. This branch is responsible for the administration and enforcement of federal laws such as the Food and Drugs Act, the Proprietary or Patent Medicine

The diagram shows a prescription form with three callout boxes:

- LINE #1** (top): Drug III Strength/Formulation/Concentration. An arrow points to the drug name and strength: "Amoxicillin 400 mg/5 mL".
- LINE #2** (bottom right): Dose/Volume III Route III Frequency III Tx length. An arrow points to the dosage and frequency: "6.5 mL by mouth twice daily for 10 days".
- LINE #3** (bottom left): Quantity to dispense. An arrow points to the quantity: "Disp# 130 mL".

The prescription form itself contains the following fields:

- Header:** "LINE #1 Drug III Strength/Formulation/Concentration" (with a callout box), "Date: _____", "Patient name: _____", "DOB: _____".
- Body:** "Amoxicillin 400 mg/5 mL", "6.5 mL by mouth twice daily for 10 days", "Disp# 130 mL".
- Signature/Refill Section:** "Signature: _____", "NPI: _____", "Refills: _____", "DEA: _____", and a checkbox for "no generics".
- Footer:** "LINE #2 Dose/Volume III Route III Frequency III Tx length" (with a callout box) and "LINE #3 Quantity to dispense" (with a callout box).

Fig. 2.1 Example of a valid prescription.

Act, and the Controlled Drugs and Substances Act. These acts, together with provincial acts and regulations that cover the sale of drugs and those that cover the healthcare professions, are designed to protect the Canadian consumer from health hazards; misleading ads about drugs, cosmetics, and devices; and impure food and drugs. The Canadian Food and Drugs Act divides drugs into various categories. Regulations covering the various categories or schedules of drugs differ from those in the United States. There are three major classes of drugs under the Food and Drugs Act: non-prescription drugs, prescription drugs, and restricted drugs.

The Proprietary or Patent Medicine Act provides for a class of products that may be sold to the general public by anyone. The drug formula is proprietary (a trade secret); it is not found in the official drug manuals or printed on the label. The formulas for all such proprietary nonpharmacologic drugs must be registered, and a license must be issued under the Proprietary or Patent Medicine Act. The nurse needs to be aware of patients taking such drugs in the case of possible drug interactions.

The Canadian Controlled Drugs and Substances Act covers the possession, sale, manufacture, production, and distribution of opioids (narcotics) in Canada. Only authorized people may have opioids in their possession. All people authorized to be in possession of an opioid must keep a record of the names and quantities of all opioids dispensed, and they must ensure their safekeeping. Nurses are in violation of this act if they are guilty of illegal possession of opioids.

OTC drugs are regulated in Canada by the Canadian Food and Drugs Act. These drugs can be purchased without a prescription, but there are rules about packaging, labeling, and dispensing of the drugs. Nurses

must be aware of the risks these drugs have and watch for possible adverse effects and interactions with other drugs. OTC drugs available in Canada differ from those available in the United States.

THE DRUG ORDER

LEGAL PRESCRIPTIONS

Both state law and agency policy require that all drugs given in hospitals and long-term care facilities must be ordered by licensed healthcare providers acting within their scope of practice. This generally restricts **prescriptive authority** (the authority to write an order or prescription for drugs) to licensed physicians, dentists, nurse practitioners, nurse midwives, nurse anesthetists, and physician assistants. Providers who write the prescriptions are also called *prescribers*. Prescriptions for a hospitalized patient are written in the specified area of a patient's chart or recorded in the electronic record, and the pharmacy is notified. In some agencies, the order must be transcribed or rewritten by an authorized individual onto a special pharmacy order form, which is then sent to the pharmacy. Assisted living facilities and long-term care facilities may have providers who evaluate the patients and order or issue recurring orders for patient drugs. Every time a patient has a prescription filled, the pharmacy is required to give information about the drug and how it is to be given.

A legal prescription order must contain:

- Patient's full name
- Date
- Name of drug
- Route of administration
- Dose
- Frequency
- Duration
- Signature of prescriber

Additional details about how to give the drug may also be written—for example, "Take with meals," "Avoid milk products with this drug," "(number of) refills available," "May cause drowsiness," or "Please label." Pharmacies also require the patient's age and address on the prescription. This information may help the pharmacist ensure the right drug dosage for the patient (e.g., child, older adult) and verify the patient's identity (Fig. 2.1).

In emergencies or if the provider is not available on site, a *verbal order*, usually over the telephone, may be given. All agencies that employ nurses have policies about verbal orders. The agency decides who is authorized to take, transcribe, and implement verbal orders. The nurse taking the order is responsible for writing the order on the order form in the medical record, including the name of the nurse and the name of the prescriber. Many institutions also require that a note be written to indicate that the order was read back to the prescriber for validation. The prescriber must

then cosign the order, usually within 24 hours, for it to be valid. The receiving and transcribing of verbal telephone orders may be the responsibility of the registered nurse (RN). *It is your responsibility as an LPN/VN to be very familiar with the verbal order policy of the institution where you are practicing.*

TYPES OF DRUG ORDERS

Drug orders are classified into one of four types: the standing order, the emergency or stat order, the single order, and the as needed or PRN order.

A **standing drug order** indicates that the drug is to be given until discontinued or for a certain number of doses. Hospital or institutional policy usually dictates that most standing orders expire after a certain number of days. A renewal order, such as the following, must then be written by the prescriber before the drug may be continued:

- amoxicillin 500 mg orally every 8 hours for 10 days
- ibuprofen 600 mg orally every 6 hours prn

An **emergency or stat drug order** is a one-time order to be given immediately, such as the following:

- diphenhydramine 50 mg IV stat

A **single drug order** is a one-time order, such as the following, to be given at a specified time:

- cefazolin 1 g IV at 10:00 a.m. before surgery

An **as needed or PRN drug order** is an order for a drug to be given as needed based on a nurse's judgment of safety and patient need, such as the following:

- docusate 100 mg orally at bedtime as needed for constipation

STATE LAW AND HEALTHCARE AGENCY POLICIES

Although many regulations about giving drugs come from federal laws, details about who may prescribe and who may give drugs are set by each individual state. This authority is spelled out for nurses in the **Nurse Practice Act** of each state and can be found at the National Council of State Boards of Nursing Web site.



Bookmark This!

National Council of State Boards of Nursing:
<https://www.ncsbn.org/npa.htm>

Differences in practice from state to state make it essential that nurses learn what is legal regarding drug administration and that they make sure they abide by the rules and regulations. Because nurses may move from state to state, they must know exactly what is in the Nurse Practice Act of each state where they are licensed to work. Nurses often move between jobs, and some states recognize the nursing license of another state through an agreement called the *Nurse Licensure Compact*. There is a growing list of states that participate in the compact (available at <https://www.ncsbn.org>).

State rules about nursing practice often list the basic or minimum standards of practice. Agency or institutional policies and guidelines may be more specific or more restrictive than state Nurse Practice Acts. Agencies that employ nurses must provide written policy statements about the educational preparation for nurses permitted to give drugs and an orientation to particular policies, procedures, and recordkeeping rules of the agency. When you accept a nursing job, it is implied that you are willing to obey the policies or procedures of that institution. It may be an agency's policy to require employment for a certain period, completion of special orientation and training sessions, and passage of a probation period before a nurse is permitted to give drugs. Even when you have the legal authority to give drugs, a valid drug order signed by an authorized prescriber is needed.

Giving drugs is a responsibility reserved for nurses who are named by law to give drugs and who can document the appropriate educational preparation to do so. Nurses who give drugs to patients accept **professional responsibility** for giving drugs correctly, ethically, and legally. This means nurses must accept *ethical and legal* responsibility for good judgment and actions in drug administration and monitoring the effects of drugs given. Agencies expect nurses to carry out the steps of the nursing process, and you are responsible for good assessment, planning, implementation, and evaluation of the patient when drugs are given. You will be held responsible for failure to perform any of these steps well.

Medication Technician or Aides

More than half the states have recognized the role of medication technician or aide in the giving of drugs to patients under the supervision of a licensed nurse. Medication technicians or aides are unlicensed assistive personnel who may obtain certification by taking the Medication Aide Certification Exam. As unlicensed assistive personnel, the medication technician or aide must hold the Certified Nurse Assistant/Aide (CNA) credential, complete a state-approved Medication Assistant program, and meet all other state requirements to become registered, which includes a written competency examination and may, in some instances, include a clinical competency evaluation. The responsibilities of a medication technician or aide include the preparation, distribution, and monitoring of the effects of a patient's prescribed drugs. A national survey of 3,455 medication aides (Budden, 2012) found that medication technicians or aides were asked to perform duties for which they were not trained, such as calling physicians to change medication orders, giving controlled drugs, and making decisions about giving or not giving insulin. These activities are all beyond the scope of an aide because they require assessment skills and nursing judgment. As an LPN/LVN, you are responsible for the supervision of medication technicians

or aides as they carry out their duties regarding administering drugs to patients under your care.

The 9 Rights of Drug Administration

The nursing process is a helpful system to be used when giving drugs. There is a professional requirement and an implied ethical and legal requirement that nurses use this process. You must learn information about the patient's medical diagnosis, medical history, current symptoms, allergies, and current drugs taken. You are responsible for learning about all your patients' prescribed drugs, including the dosage, route of administration, expected response, adverse reactions, and the monitoring needed to ensure that the drug is working as it should and to observe for drug interactions. You are also responsible for following all laws and agency policies that are related to giving drugs, including the *9 Rights of Drug Administration* (Table 2.2). You also are responsible for teaching the patient and the family what they need to know for continued and safe administration of this drug.

DRUG ADMINISTRATION SYSTEMS

One critical nursing responsibility is to check that the drug orders for your patient are correct. You may need to confirm the order you have (using a drug Kardex or other paper drug system or using the electronic medical record [EMR] in a computerized system) against the original order by the provider. Every agency has its own drug order, distribution, and recording system for the patient's health record. Agency policy will tell you what information is to be placed in each section. After you give the drug or drugs ordered, you must record all required drug administration information.

An EMR system is a software platform that allows the electronic entry, storage, and maintenance of digital medical data. Integrated within an EMR, many facilities now use a barcoded drug administration system to allow drug orders to be sent to the pharmacy when they are written; the drugs are sent to the patient's room or floor, and the drug is then taken to the patient's bedside. The patient's barcoded wristband and the barcode on each drug are scanned by the nurse using a handheld device (Fig. 2.2). This ensures that the right patient is getting the right drug as noted in the drug order. As the patient is observed taking the drug, the nurse notes that the drug has been given and the chart is electronically updated with this information.

An EMR and an integrated barcoded drug system have several advantages. The use of a computer to create the record prevents illegible clinician handwriting, a common cause of drug errors. These systems also avoid having orders transcribed several times as they are sent to the pharmacy, given to the nurse, and so on; this results in fewer errors. Many systems are designed to indicate whether the dose ordered by the clinician is out of the acceptable dosage range or would interact

Table 2.2 The 9 Rights of Drug Administration

RIGHT PATIENT	CHECK THE PATIENT'S NAME USING TWO METHODS TO IDENTIFY THE PATIENT.
Right drug	Check drug order. Check drug label.
Right dose	Check drug order. Confirm drug dose is appropriate.
Right route	Confirm the drug can be given by the route ordered. Confirm the patient can take or receive the drug by the route ordered.
Right time	Confirm the times the drug is ordered are correct. Check for correct time before giving the drug. Check the last time the drug was given.
Right reason	Confirm the reason or need for the drug.
Right documentation	Document drug administration after the drug is given. Chart the time, route, and any other specific information as necessary.
Right response	Confirm the drug has had the desired effect. Document any monitoring needed or adverse effects as needed.
Right to refuse	The patient has a right to refuse any prescribed drug.



Fig. 2.2 Electronic scan of wristband. (From deWit, S. C., & O'Neill, P. (2014). *Fundamental concepts and skills for nursing* (4th ed.). Saunders.)

with another ordered drug, whether there are other dosing errors, or if the patient has a recorded allergy to a prescribed drug.

KARDEX AND ELECTRONIC DRUG SYSTEMS

The Kardex is a pen-and-paper, flip-file card system that has been used for many years. It contains

- Ampules, 54, 55f
- Amylin analogs, 372t, 373–374
- Amyotrophic lateral sclerosis (ALS)
- antioxidant, 200
 - drugs for, 198–200, 200t
 - glutamine antagonists, 199–200
- Anabolic steroids, 350
- Anaerobic bacteria, 74
- Analgesics, 236
- nonopioid centrally acting, 243–244
 - opioid agonist, 238t. *See also* Opioid agonists
 - opioid agonist-antagonist, 242–243
 - for pain management, 236–244
- Anaphylactic reaction, to drug, 33, 33b
- Anaphylaxis, 78
- Androgen receptor antagonists, 342, 342t
- Androgens, 350
- action and uses, 350
 - adverse reactions, 350–351
 - drug interactions, 351, 351t
 - nursing implications and patient teaching, 351–352
 - side effects, 350
- Anesthesia, 248–250
- drugs for, 248–249, 248t
 - mechanism of action, 248
 - types of, 248
- Anesthetics, 248
- Angina, 150, 356
- acute, 165
 - antianginals for, 165
 - drugs used for, 165–172
 - nitrates for, 165–167
- Angioedema, 78, 163f, 375f
- Angiotensin I, 158
- Angiotensin II, 158
- Angiotensin II receptor blocker (ARB), 156–157
- Angiotensin-converting enzyme (ACE), 156–157
- Angiotensin-converting enzyme inhibitors (ACE-Is), 156–157
- Anorexia, 86, 239, 318
- Antacids, 281t
- action and uses, 280–282
 - adverse reactions, 282–283
 - drug interactions, 283
 - nursing implications and patient teaching, 283
 - side effects, 282
- Antagonistic effect, in drug interactions, 29, 29b, 34
- Antagonists, 159
- Anterior chamber, 399
- Anterior segment, eye, 399
- Anthelmintic drugs, 103t
- action and uses, 104
 - drug interactions, 105
 - nursing implications and patient teaching, 105
 - side effects and adverse reactions, 105
- Anthracycline antibiotic agents, 337t
- Antianginals, 165
- Antianxiety drugs, 208–210
- action and uses, 209
 - drug interactions, 209
 - nursing implications and patient teaching, 209–210
 - side effects and adverse reactions, 209
- Antibacterial agents, 74–75, 92
- Antibiotics, 75–88
- aminoglycosides, 85
 - antitumor, 337–338, 337t
 - cephalosporins as, 81
 - fluoroquinolones as, 86–88
 - macrolides, 83–85
 - penicillins as, 76–81, 77f, 79t
 - sulfonamides as, 86
 - tetracyclines as, 82–83
- Antibody, 300
- Antibody titer, 304–305
- Anticholinergic drugs, 288t, 291, 293t
- Anticoagulants, 315–327, 316t
- direct thrombin inhibitors, 319–320
 - erythropoiesis-stimulating agent, 326–327
 - fibrinolytic drugs, 324–326
 - foods interfering with, 318b
 - indirect thrombin inhibitors, 320–322
 - platelet inhibitors, 316–319
 - vitamin K antagonists, 322–324
- Anticonvulsants, 247–248
- Anticytomegalovirus drugs, 112t
- Antidepressants, 210–211, 212t
- for pain management, 247, 247b–248b
- Antidiarrheals, 291, 291b
- action and uses, 291–292
 - adverse reactions, 292
 - nursing implications and patient teaching, 292
 - side effects, 292
- Antidysrhythmics, 167–171
- action, 168
 - uses, 168
- Antiemetic drugs, 273–280, 274t
- nursing considerations, 276b
 - serotonin (5-HT₃) receptor antagonists, 274–276
- Antiepileptic drug (AED), 188. *See also* Anticonvulsants
- actions and uses, 189–191
 - adverse reactions, 191–192
 - drug interactions, 192
 - epidiolex (Cannabidiol), 193t, 197
 - levetiracetam, 193t, 196–197
 - newer, 192–197, 192b, 194t
 - lacosamide, 193t, 195–196
 - lamotrigine, 193t, 194–195
 - levetiracetam, 193t, 196–197
 - oxcarbazepine, 192, 193t
 - topiramate, 193t, 196
 - nursing considerations, 189b
 - patient and family teaching, 189b
 - side effects, 191
 - traditional, 188–192, 190t
- Antifungals, 99t
- action and uses, 98
 - drug interactions, 98
 - nursing implications and patient teaching
 - assessment, 100–101, 101b
 - evaluation, 101, 101b
 - patient and family teaching, 101
 - planning and implementation, 101
 - side effects and adverse reactions, 98, 98b
 - topical drugs, testing points for, 100b
- Antigen, 125, 300
- Antigout drugs, 267t
- actions, 266
 - adverse reactions, 266
 - drug interactions, 266–267
 - nursing implications and patient teaching, 267
 - side effects, 266
 - uses, 266
- Antihistamines, 127t
- actions, 125–128
 - adverse effects, 128
 - drug interactions, 128–129
 - nursing implications and patient teaching, 129
 - side effects, 128
 - uses, 128
- Antihyperlipidemics, 150–156
- Antihypertensives, 156–165
- action of, 157
 - common, 160t
 - nursing implications, 157, 157b
 - side effects, 163
 - uses, 163
- Anti-infectives, 74–75
- Anti-inflammatory drugs, 136t, 137, 255
- Antimalarials, 102, 103t
- Antimetabolites, 98, 336–337, 336t, 336b
- action, 336
 - adverse reactions, 336
 - nursing implications and patient teaching, 336–337
 - side effects, 336
 - uses, 336
- Antimicrobial drugs, 74–75, 97
- Antimicrobial resistance, 75, 96–97
- Antimicrobial sensitivity, 74
- Antimitotic agents, 334, 339, 339t
- Antioxidant, 200
- Antiparasitic drugs, 102, 103t
- Antiproliferative drugs, 308–309, 309t
- Antiprotozoal drugs
- action and uses, 102
 - drug interactions, 102
 - nursing implications and patient teaching, 102–104
 - side effects and adverse reactions, 102
- Antipsychotics, 222–230, 224t
- atypical, 223
 - typical, 223
- Antirejection drugs, 308
- Antiretroviral therapy (ART), 116
- Antiretrovirals, 115–121
- actions of, 119
 - adverse effects, 120
 - nursing implications and patient teaching, 120–121
 - pre-exposure prophylaxis, 120
 - side effects, 120
- Anti-RSV drugs, 112t
- Antispasmodic drugs, 288t, 291, 293t
- Antithyroid drugs, 356t, 358–359
- actions and uses, 358
 - adverse effects, 358
 - drug interactions, 359
 - nursing implications and patient teaching, 359
 - side effects, 358
- Antitubercular drugs, 92–97
- action and uses, 95
 - adverse reactions, 96

- Antitubercular drugs (*Continued*)
 drug interactions, 96
 nursing implications and patient teaching, 96–97
 pregnant and breast-feeding women, 95
 side effects, 95–96
- Antitumor antibiotics, 337–338, 337t
 action, 337
 adverse reactions, 337
 nonanthracycline, 337
 nursing implications and patient teaching, 337–338
 side effects, 337
 uses, 337
- Antitussives, 138–140
 action and uses, 138–139
 adverse reactions, 139–140
 drug interactions, 139–140
 nursing implications and patient teaching, 139t, 140
 side effects, 139–140
- Antivirals, 109–114
 adverse reactions, 113
 cytomegalovirus, 110–111, 112t
 definition, 109
 drug interactions, 113
 hepatitis B and hepatitis C viruses, 111–113, 113t
 for herpes simplex virus infections, 109, 110t
 for influenza, 109–110, 110t
 nursing implications and patient teaching, 113–114
 respiratory syncytial virus, 110–111
 side effects, adverse reactions, 113
- Anxiety
 drugs for, 206–210
 Parkinson's disease and, 178
- Anxiety disorder, 208–209
- Anxiolytics, 209
- Apixaban, 316t, 319
- APOE-e4* gene, 184
- Apraclonidine, 407t
- Aprepitant, 274t
- Aqueous humor, 399
- Arachidonic acid cascade, 255f
- Areflexia, 191
- Arformoterol, 135t
- Aripiprazole, 224t
- Aromatase inhibitors (AIs), 341–342, 341t
- Arrhythmia, 167–168
- Arthritis drugs, 254–270
- Arthropathy, 87–88
- Artificially acquired active immunity, 301, 301f
- Artificially acquired passive immunity, 301f, 302, 302b
- As needed or PRN drug order, 19
- ASA. *See* Acetylsalicylic acid
- Ascending loop of Henle, 144
- Aseptic technique, 48
- Aspirin, 246, 246b, 257t, 316t. *See also* Acetylsalicylic acid
 bisphosphonates, 386
- Assessment
 on corticosteroids, 262–263
 definition, 2
 on disease-modifying antirheumatic drug, 265
- Assessment (*Continued*)
 factors to consider in, 3–4
 nonsteroidal anti-inflammatory drug, 258–259
 in nursing process, 2–4, 4b
- Asthma, 132, 132f
 drug therapy, 133–137
- Asthma controller drugs, 133, 133b
- Asthma reliever drugs, 133, 133b
- Ataxia, 191
- Atazanavir, 117t
- Atenolol, 160t
- Atherosclerosis, 150
- Atorvastatin, 154t
- Atovaquone, 103t
- Atripla, 117t
- Attenuated vaccine, 302
- Atypical antidepressants, 210, 212t
- Atypical antipsychotics, 224t
 action and uses, 227
 drug interactions, 228
 nursing implications and patient teaching, 228–229
 side effects and adverse reactions, 227–228
- Auditory perception, 397
- Auscultation, 3
- Availability, drug, 35
- Azacitidine, 336t
- Azathioprine, 309t
- Azithromycin, 84t
- Azoles, 98, 99t
- B**
- B lymphocytes, 300
- Bacteria, 74
- Bactericidal agents, 75, 95
 sites of action of, on bacterial pathogens, 77f
- Bacteriostatic agents, 75, 95
 sites of action of, on bacterial pathogens, 77f
- Baloxavir, 109, 110t
- Bazedoxifene, 388t
- Beclomethasone, 136t
- Bendamustine, 335t
- Benign prostatic hyperplasia (BPH),
 drugs for, 148
- Benzodiazepine agonist, 206–208, 207t
- Benzodiazepines (BNZs), 225
 for anxiety, 206, 207t
 pregnancy, 208b
 for sleep, 206
- Benzonatate, 139t
- Beta-blockers, 159, 160t, 169t, 404
 sites of action for, 162f
- Beta-adrenergic antagonists, 406t
 actions, 404
 adverse reactions, 404–405
 nursing implications and patient teaching, 405–407
 side effects, 404
- Beta-interferon, 199t
- Beta-lactamases, 75
- Betamethasone, 260t
- Betaxolol hydrochloride, 406t
- Biguanides, 367, 367t, 369
- Biktarvy, 117t
- Bile acid sequestrants, 155
- Bimatoprost, 406t
- Bioequivalence, 34
- Biological response modifiers (BRM),
 198, 199t
- Biosynthetic vaccines, 302
- Biotransformation, of drug, 31
- Bipolar disorder, 210
- Bipolar illness, 220
- Birth control pills (BCPs), 348
- Bisacodyl, 239, 288t, 290t
- Bismuth subsalicylate, 281t, 291–292
- Bisphosphonates, 386–387, 388t
 action, 386
 adverse effects, 386
 nursing implications and patient teaching, 386–387
 side effects, 386
 uses, 386
- Black box warning, 23, 24f
- Bladder anesthetics, 148–149
- Bleb, 54–56
- Bleomycin, 337t
- Blockers, 159
- Blood clotting, 314–315
- Blood coagulation and clot lysis, 315f
- Blood pressure, 156, 156t
- Blood thinners, 315
- Blood–brain barrier, 38
- Body surface area (BSA), 46
- Bone cells, 385
- Bone density, 385b
- Bone marrow suppression, 339–340
- Bone mass, and osteoporosis, 387b
- Bone remodeling, 385
- Bone resorption, 385
- Bony ossicles, 396
- Bradycardia, 191, 239
- Bradypnea, 239
- Brain, function of, 177
- Brand name, of drug, 28
- Breast cancer, hormone therapy for,
 341–342, 341b
 adverse effects of, 342
 drugs categories, 341, 341t
 side effects of, 342
- Breast-feeding, 75b
 antithyroid drugs, 359b
- Breast-feeding patients, lidocaine, 249b
- Brinzolamide, 409t
- Broad-spectrum drugs, 75
- Brompheniramine, 127t
- Bronchoconstriction, 132
- Bronchodilators, 133–137
 actions, 133–134
 adverse reactions, 135
 drug interactions, 135–136
 nursing implications and patient teaching, 136–137
 side effects, 134–135
 uses, 134
- Buccal (route) administration, 30, 65, 67b
- Budesonide, 136t
- Bulk-forming laxatives, 286, 288t, 290t.
See also Laxatives
- Bullous pemphigoid, 375f
- Bumetanide, 146t
- Bupivacaine, 248–249, 248t, 249b
- Buprenorphine, 238t, 240, 242, 242t, 242b
- Bupropion, 212t
- Buspirone, 207t

Busulfan, 335t
Butorphanol, 238t, 242, 242t, 242b

- C**
- Cabenuva, 117t
- Calcineurin inhibitors, 309t, 310
- Calcitonin, 388t, 389
action, 389
adverse effects, 389
nursing implications and patient teaching, 389
side effects, 389
uses, 389
- Calcitonin-salmon, 388t
- Calcium, 391–392, 425–426
action, 391
adverse effects, 391
nursing implications and patient teaching, 391–392
side effects, 391
uses, 391
- Calcium carbonate, 281t
- Calcium channel blockers, 159, 169t
- Canada
drug importation from, 18
drug regulations in, 17–18
- Canadian Controlled Drugs and Substances Act, 18
- Canadian drug legislation, 17–18
- Canadian Food and Drugs Act, 17–18
- Canagliflozin, 374t
- Cancer
causes of, 332–333
cell biology, 332
definition, 331, 332b
development, 332
invasion and migration, 332, 333f
- Cancer cells, 331, 331b
normal and, characteristics of, 332, 333t
- Cancer pain, 234, 235t
- Cancer treatment
approaches, 333
drugs for, 331–344
hormone therapy for, 341–343
traditional chemotherapy, 334–341, 334b
- Candesartan, 160t
- Candida, 74
- Cannabidiol (CBD), 418
- Cannabinoids, 274t, 278–279
action and uses, 278
adverse reactions, 278
drug interactions, 278–279
nursing implications and patient teaching, 279
side effects, 278
- Cannabis, 417–419
action and uses, 418
drug interactions, 418
endocannabinoid system, 417–418
nursing implications and patient teaching, 418–419
side effects, 418
- Capecitabine, 336t
- Capreomycin, 92–93, 95t
- Capsule, 49
crushing, 14
- Captopril, 160t
- Carbachol, 407t
- Carbamazepine, 190t, 221t
actions and uses, 191
adverse reactions, 191
side effects, 191
- Carbamide peroxide, 399t
- Carbapenems, 79t
- Carbazitaxel, 339t
- Carbidopa/levodopa, 180t, 181
- Carbonic anhydrase inhibitor (CAI), 409t
action and uses, 409
adverse reactions, 409
nursing implications and patient teaching, 409–410
side effects, 409
- Carboplatin, 335t
- Carboxypenicillins, 78
- Carcinogenesis, 332
- Carcinogens, 332
- Cardiac arrest, 201
- Cardiac dysrhythmias, 423
- Cardiac glycosides, 169t
- Cardiovascular system, 152f
antihyperlipidemics and, 150–156.
See also Antihyperlipidemics
antihypertensives, 156–165
drugs affecting, 149–172
nonstatin antihyperlipidemic drugs and, 155
- Carmustine, 335t
- Carteolol, 406t
- Cartridge, 54
- Carvedilol, 160t
- Cascade, 315
- Catecholamines, 159
- Catechol-*O*-methyltransferase (COMT) inhibitors, 180t
action and uses, 183
drug interactions, 183
nursing implications and patient teaching, 183
side effects and adverse reactions, 183
- Cation, 427
- CCR5 antagonist, 116
- Cefaclor, 79t
- Cefazolin, 79t
- Cefdinir, 79t
- Cefepime, 79t
- Ceftriaxone, 79t
- Cefuroxime, 79t
- Celecoxib, 257t
- Cell cycle, 332, 332f
- Cell division, 332, 332b
- Cell wall synthesis inhibitors, 77, 79t, 81–82
drug interactions with, 82
side effects and adverse reactions to, 82
- Center for Nutrition Policy and Promotion, 389b
- Centers for Disease Control and Prevention, 211b
- Central nervous system
drug therapy for, 176–203
functions, 177–178, 177f
- Centrally acting alpha2-adrenergic agonists, 163
- Cephalexin, 79t
- Cephalosporins, 81b
action, 81
- Cephalosporins (*Continued*)
adverse reactions, 81
drug interactions, 81
nursing implications, 79t, 81
patient teaching, 81
side effects, 81
uses, 81
- Cerumen, 396
- Cerumenolytics, 398, 399t
- Cetirizine, 127t
- Charcot-Marie-Tooth disease, 340b
- Chemical name, of drug, 28
- Chemotherapy
combination, 341
drug categories, 334, 334b
traditional, 334–341
- Children, peripheral neuropathy, 340b
- Chlorambucil, 335t
- Chloride channel activators, 293t
action and uses, 293
nursing implications and patient teaching, 293–294
side effects/adverse effects, 293
- Chloroquine, 102, 103t
- Chlorothiazide, 146t
- Chlorpromazine, 224t
- Cholecalciferol, 424
- Cholelithiasis, 155
- Cholestyramine, 82
- Cholinergic agonists, 186, 186b
- Cholinergic antagonists, 133–134, 135t
- Cholinergic drugs, 407t
action and uses, 408
adverse reactions, 408
nursing implications and patient teaching, 408–409
side effects, 408
- Cholinesterase inhibitors, 186t, 201
action and uses, 185–186
drug interactions, 186–187
nursing implications and patient teaching, 187
side effects and adverse reactions, 186, 186b
- Chronic bronchitis, 132
- Chronic diarrhea, 286
- Chronic obstructive pulmonary disease (COPD), 132–133
drug therapy, 133–137
- Chronic pain, 234, 234b, 235t
- Cidofovir, 111, 112t
- Ciliary body, 399
- Cilostazol, 316t
- Ciprofloxacin, 87t
- Cisplatin, 335t
- Cladribine, 336t
- Clarithromycin, 84t
- Clark's rule, in pediatric dosage calculation, 46
- Client problem-solving process (nursing process), 2
- Clindamycin, 84t, 85
- Clinical judgment, 10–11, 11b
- Clofarabine, 336t
- Clonidine, 160t, 243, 243b
- Clopidogrel, 316t, 317–318
- Clostridium difficile* infection, 284
- Clot, 315. *See also* Blood clotting
- Clot busters, 324
- Clotting system, 318, 318b

- Cochlea, 396–397
 Codeine, 238t
 Codeine-containing antitussives, 139t
 Cognitive impairment, 217, 223
 Cognitive processes, 10
 Cognitive skills, clinical judgment, 10, 11b
 Cogwheel rigidity, 178
 Colestipol, 82
 Collecting duct, 145
 Columbia-Suicide Severity Rating Scale (C-SSRS), 215t
 Combination antiretroviral therapy (cART), 116
 Combination chemotherapy, 341
 Combivir, 117t
 Complementary and alternative medicine (CAM), 414
 product labeling, 416–417
 Complementary medicine, 414
 Complera, 117t
 Confused drug names, 6, 7t
 Conjugated estrogens, 348t
 Conjugated estrogens plus progesterin, 348t
 Constipation, 239, 273
 causes, 285
 drugs for, 286–291, 288t
 episodes, 285
 nursing considerations for, 291b
 occurrence of, 285f
 signs and symptoms of, 285b
 Constrict, 130
 Continuation phase, 92
 Continuous aerosol therapy, 66, 68f
 Continuous pain, 235t
 Contraindication, definition of, 5
 Controlled substances, 14–15
 classification, 15t
 definition of, 14, 17b
 distribution, 16–17
 Convulsion, 188
 COPD (chronic obstructive pulmonary disease), 132–133
 drug therapy, 133–137
 Cornea, 399
 Corticosteroid nasal sprays, 131
 Corticosteroid receptor blockers, 361t
 Corticosteroids, 130, 245, 259, 359
 actions, 259–260
 adrenal production of cortisol, 262f
 adverse reactions, 261–262
 drug interactions, 262
 inhaled, 136t
 nursing implications and patient teaching, 262–264
 oral, 260t, 262f
 parenteral, 260t
 physical changes, 261, 261f
 side effects, 260–261, 261b
 topical, 260t
 uses, 260
 Cortisol, 261–262, 359
 Cortisone acetate, 260t
 Council for Responsible Nutrition, 419
 Covert drug administration, 13–14
 COVID-19, 109, 114–115, 115b
 drugs for, 114t
 vaccination, 307–308
 viral vector vaccines, 303
 Cromolyn sodium (NasalCrom), 127t
 Cromones, 130
 Cross-sensitivity, 81
 Cushing syndrome, 261, 261f, 360
 “Cushingoid” appearance, 261f
 Cyanocobalamin, 420t, 423
 Cyclins, 332
 Cyclobenzaprine, 246–247, 246t, 247b
 Cyclooxygenase (COX), 255
 Cyclooxygenase 2 (COX-2), 257t
 Cyclooxygenase 1 and 2 inhibitors, 257t
 Cyclophosphamide, 335t
 Cyclosporine, 309t
 Cytarabine, 336t
 Cytochrome P-450 system, 31
 Cytomegalovirus (CMV), antiviral drugs for, 110–111, 112t
 Cytoprotective drugs, 281t, 285, 291–292
 Cytotoxic drugs, 334
D
 Dabigatran, 316t, 319
 Dacarbazine, 335t
 Daclizumab, 199t
 Dactinomycin, 337t
 Dalfampridine, 198, 199t
 Dalfopristin/quinupristin, 84t, 85
 Dalteparin, 316t
 Dapagliflozin, 374t
 Darbepoetin alfa, 326t
 Darifenacin, 151t
 Darunavir, 117t
 Data
 definition, 2
 objective, 3
 subjective, 3
 Daunorubicin, 337, 337t
 Decitabine, 336t
 Decongestants
 actions and uses, 130, 131t
 adverse reactions, 130–131
 drug interactions, 131
 nursing implications and patient teaching, 131–132, 131t
 side effects, 130
 Deep vein thrombosis (DVT), 319
 Dehydration, 147
 Delavirdine, 119b
 Delirium, 181, 217, 222–223
 Delusions, 178
 Dementia, 184
 Dengue, 303
 Denosumab, 388t
 Dependence, 240
 Depression, 210
 categories of, 210
 examples, 211f
 Parkinson’s disease and, 178
 symptoms of, 210, 210b
 Descovy, 120
 Desflurane, 250t
 Desired action, 33
 Desirudin, 316t
 Desogestrel, 349t
 Detrusor muscle, 148–149
 Deutetrabenazine (Austedo), 229t
 Dexamethasone, 260t
 Dextromethorphan, 139t
 Diabetes mellitus (DM)
 blood glucose control in, 365
 Diabetes mellitus (DM) (*Continued*)
 classification of, 366
 definition of, 365
 drugs for, 364–383
 management of, 366–382
 Diabetes mellitus type 2, 365–366
 Diagnosis, in nursing process, 4
 Diarrhea, 273
 causes, 286, 286b
 drugs for, 285–292, 288t
 episodes, 286
 nursing considerations for, 292b
 pathophysiology, 286, 286f
 Diazepam, 31, 207t
 Diclofenac, 257t
 Dicyclomine, 288t
 Didanosine, 117t
 Dietary supplement, 416–417
 Dig level, 171
 Digestion, 272
 mechanical and chemical processes of, 272, 272f
 Digestive enzymes, 273
 Digestive system, 272–273, 272f. *See also*
 Gastrointestinal tract
 Digital nasolacrimal occlusion, 401f
 Digoxin, 169t, 171, 172b
 older adults, 172b
 Dihydrotestosterone (DHT) inhibitors, 149t
 Diltiazem, 160t, 169t
 Dimetapp. *See* Brompheniramine
 Dimethyl fumarate, 198, 199t
 Dipeptidyl peptidase-4 (DPP-4), 374–375, 374t
 Diphenhydramine, 127t
 Diphenoxylate, 288t
 Dipivefrin hydrochloride, 407t
 Direct thrombin inhibitors (DTIs), 316t
 actions, 319
 adverse reaction, 319
 drug interactions, 319
 nursing implications and patient teaching, 319–320
 side effects, 319
 uses, 319
 Direct-acting stimuli, 273
 Disease-modifying antirheumatic drug (DMARD), 264, 265t
 actions, 264
 adverse reactions, 264
 biologic, 264
 conventional, 264
 drug interactions, 264–265
 nursing implications and patient teaching, 265–266
 risk and toxic effects, 264
 side effects, 264
 uses, 264
 Disopyramide, 169t
 Displacement, in drug interactions, 34
 Distal convoluted tubule, 144
 Distribution, drug, 31, 32f
 in older adult, 36–37
 in pediatric patients, 36
 Diuretics, 160t
 actions, 144–148
 adverse effects, 147
 assessment of, 147
 categories of, 146t

- Diuretics (*Continued*)
 common, 146t
 drug interactions, 147
 loop, 145, 146t
 nursing implications and patient teaching, 147–148
 older adults and, 145b
 potassium-sparing, 145
 pregnancy and, 145b
 side effects, 145–147
 uses, 145
- Divalproex sodium, 221t
- DMARDs (disease-modifying antirheumatic drugs), 264–266, 265t
- DNA polymerase inhibitors, 109, 111, 112t–113t
- Docetaxel, 339t
- Documentation. *See also* Patient charts
 drug administration, 9
- Docusate, 288t, 290t
- Dolutegravir, 117t
- Donepezil, for Alzheimer's disease, 186t
- Dopamine, 178
- Dopamine agonists, 180t
 action and uses, 179–181
 drug interactions, 181–182
 nursing implications and patient teaching, 182–183
 side effects and adverse reactions, 181
- Dopamine antagonists, 277
- Dopamine system stabilizers (DSS), 224t, 227
- Dorzolamide, 409t
- Dosage drug calculation, 44–48
 for children, 46
 fraction method for, 44–45
 for infants, 46
 metric system, 44, 44f
 ratio and proportion method for, 45
 solving steps, 45b
- Doxazosin, 160t
- Doxorubicin, 337, 337t
- Doxycycline, 84t
- DPP-4 inhibitors, 374–375
- Dronabinol, 274t
- Drop factor, in IV infusion calculation, 46–47, 48b
- Drospirenone, 349t
- Drug(s)
 absorption of, 29–31
 abuse, 14
 actions and responses, 33b
 administration, 9 rights of, 20, 5–9, 6b, 20t
 adverse reactions to, 33. *See also* Adverse reaction/effects
 allergic reactions to, 33, 33b
 anaphylactic reaction to, 33, 33b
 for anesthesia, 248–249, 248t
 attachment, 28–29
 availability of, 35
 bioequivalence, 34
 distribution, 31, 32f
 diversion, 14
 elimination of, 31–32
 errors, 21–24
 evaluating response to
 adverse effects, 10
 side effects, 10
 therapeutic effects, 9–10
- Drug(s) (*Continued*)
 excretion of, 31–32, 32f
 hepatotoxic, 33
 high-alert, 23
 history, 4b
 hypersensitivity to, 33
 idiosyncratic responses to, 33
 metabolism of, 31, 32f
 misuse, 14
 names of
 brand, 28
 chemical, 28
 generic, 28
 trade, 28
 nephrotoxic, 33
 orders, 4–5
 over-the-counter, 14, 17
 paradoxical response to, 33
 preparations, 30–31, 31f
 prescription, 14, 17
 processes involving, 29–32
 receptor sites for, 28–29, 29f
 regulation of, 14–18
 in Canada, 17–18
 in United States, 14–18, 15t
 federal laws in, 14–17
 healthcare agency policies in, 19–20
 state law in, 19–20
 side effects of, 33
 topical, 64–65
- Drug action(s), 32–35
 adverse, 33
 desired, 33
- Drug calculation
 for insulin, 45
 for IV infusions, 46–47
 using units, 45–46, 45f
- Drug cards, 38, 38t–40t
- Drug generation, 75
- Drug interaction, 34–35
 with alcohol, 34–35
 with food, 34–35
- Drug misuse, 240
- Drug names, 28
- Drug order(s), 18–20
 legal prescriptions, 18–19, 18f
 types of, 19
- Drug susceptibility and resistance, 75
- Drug systems, electronic, 20–21, 21f, 21b
- Drug therapy
 mental health, 204–232
 in older adult, 36–37
 patient teaching considerations in, 37
 in pediatric patients, 35–36
 personal factors influencing, 35
 pregnancy and lactation and, 37–38
 special populations and, 35–38
- Drug-induced movement disorders (DIMDs), 223–226, 227b
- Dry-powder inhaler, 66, 136, 137f, 138b
- Ductless glands, 354
- Dulaglutide, 372t
- Duloxetine, 212t
- Duodenum, 273
- Dutasteride, 149t
- Dynorphins, 237–238
- Dyskinesia, 181
- Dyspepsia, 191, 318
- Dysphoria, 238
- Dyspnea, 426
- Dysrhythmia, 150, 167–168, 320
- Dysthymic disorder, 210
- Dystonia, 182
- E**
- Ear
 eardrops for, 397, 398f
 external, 403f
 inner, 397f
 middle, 396, 397f
 problems, drugs to manage, 397–398
 structure and function, 396–397
- Ear canal, 396, 398, 398b
- Ear drops, 66, 67b
- Ecchymosis, 335
- Ectoparasites, 105
- Edavarone, 200, 200t
- Edoxaban, 316t, 319
- Education. *See* Patient and family teaching
- Efavirenz, 117t, 119b
- Efgartigimod alfa, 202
- Electronic drug systems, 20–21, 21f, 21b
- Electronic medical record (EMR), 20, 20f
- Elevated blood pressure, 156
- Elimination, drug, 31–32
 in older adult, 37
 in pediatric patients, 36
- Eluxadolone, 293t
- Elvitegravir, 117t
- Emboli, 315
- Embolism, 315
- Emergency or stat drug order, 19
- Emollients/stool softeners, 288t
- Empagliflozin, 374t
- Empiric treatment, 74
- Emtricitabine, 117t
- Enalapril, 160t
- Endocannabinoid system, 417–418
- Endocrine system, 354–355, 355f. *See also* Corticosteroids; Hormone(s)
- Endonuclease inhibitor, 110t
- Endorphins, 237–238
- Enfuvirtide, 117t
- Enkephalins, 237–238
- Enlarged prostate gland, 149t
- Enoxaparin, 316t
- Entacapone, 180t
- Entecavir, 113t
- Enteral route of administration, 30, 48–51
 nasogastric, 50–51
 oral, 49–50
- Entry inhibitors, 119
- Environmental carcinogens, 332
- Environmental factors, causes cancer, 332
- Enzymes, digestive, 273
- Eplusea, 112–113
- Epidiolex (Cannabidiol), 197
- Epilepsy
 antiepileptic drugs for, 188
 definition, 188
 drugs for, 188–197. *See also* Anticonvulsants
- Epinephrine, 159
- Epirubicin, 337, 337t
- Epistaxis, 216
- Epoetin alfa, 326t

- Epzicom, 117t
 Ergocalciferol, 424
 Ertapenem, 79t
 Ertugliflozin, 374t
 Erythema, 78, 100–101
 Erythromycin, 84t
 Erythropoiesis, 326, 422
 Erythropoiesis-stimulating agent (ESA), 326
 actions, 326
 adverse reactions, 326
 nursing implications and patient teaching, 326–327, 326t
 side effects, 326
 uses, 326
 Erythropoietin, 327
Escherichia coli, 73–74
 Escitalopram, 212t
 Esomeprazole, 281t
 Estazolam, 207t
 Estrogen, 345
 drugs, 348
 growth of breast cancers, 341
 secretion
 feedback loops control over, 345–346, 346f
 and ovulation stop, 346
 Estrogen receptor antagonists, 341–342, 341t
 Estrogen/bazedoxifene, 388t
 Eszopiclone, 207t
 Etanercept, 265t
 Ethambutol, 92, 93t, 95
 Ethinyl estradiol, 349t
 Ethosuximide, 190t
 actions and uses, 191
 side effects, 191
 Ethynodiol diacetate, 349t
 Etodolac, 257t
 Etonogestrel, 349t
 Etoposide, 338t
 Etravirine, 117t
 Euphoria, 195, 238–239
 Eustachian tube, 396
 Evaluate outcomes, cognitive skills of
 clinical judgment, 11
 Evaluation
 in nursing process, 9–10, 9b
 response to drug, factors to consider in, 9–10
 Everolimus, 309t, 310
 Excitatory neurotransmitters, 177
 Excretion, drug, 31–32, 32f
 Exenatide immediate release, 372t
 Expected side effects, 10
 Expectorant, 137–138
 Extensively drug-resistant tuberculosis (XDR-TB), 93
 External ear, 396, 397f
 External eye, 403f
 Extrapyrmidal system (EPS), 223–225, 224t, 228
 Extravasation, 333
 Eye
 cornea covers, 399
 drug, self-administration of, 402b
 ointment for, instilling, 401b
 posterior segment of, 399
 problems, 398–410
 structure and function, 399–400
 Eye drops, 66, 67b
 Ezetimibe, 155
 Ezogabine, 194t
F
 Famciclovir, 110t
 Family teaching. *See* Patient and family teaching
 Famotidine, 281t
 Fasting blood glucose (FBG), 365
 Fat-soluble vitamins, 420t
 Febuxostat, 266–267
 Federal laws, on medications, 14–17
 Felbamate, 194t
 Feldene. *See* Piroxicam
 Felodipine, 160t
 Female sex hormones, 345–350
 conjugated, 348t
 egg fertilization, 345
 GnRH secretion, 345
 hormonal contraception, drugs for, 348–350, 349t
 hormone interactions for ovulation and menstruation, 345, 346f
 menopause, 346–347
 drugs for relief of, 347–348, 347b, 348t
 increased FSH levels, 347b
 reduced estrogen levels, 347b
 symptoms of, 347b
 Fenofibrate, 155
 Fentanyl, 238t
 Ferrous sulfate, 327–328, 327t
 Fexofenadine, 127t
 Fibrates, 155
 Fibric acid derivatives (fibrates), 155
 Fibrin, 315
 Fibrinogen, 315
 Fibrinolytic drugs, 324–326, 325t, 325b
 actions, 324
 adverse reaction, 325
 drug interactions, 325
 nursing implications and patient teaching, 325–326
 side effects, 325
 uses, 324–325
 Fight-or-flight response, 234
 Finasteride, 149t
 Fingolimod, 199t
 First generation antipsychotics, 223
 First-generation antihistamines, 127t
 First-line antitubercular drugs, 95
 First-pass (effect), metabolism, 31
 FLACC pain rating scale, 237f
 Flow rate, 46–47
 calculation of, 47
 factors influencing, 48
 IV calculation of, 62
 Floxuridine, 336t
 Fluconazole, 99t
 Flucytosine (Ancobon), 98
 Fludarabine, 336t
 Fludrocortisone
 action and uses, 360
 adverse effects, 360
 side effects, 360
 Fluid retention, 159b
 Flunisolide, 136t
 Fluoroquinolones
 actions, 86
 Fluoroquinolones (*Continued*)
 adverse reactions, 87–88
 drug interactions, 87–88
 nursing implications and patient teaching, 87t, 88
 side effects, 86, 88b
 uses, 86
 5-Fluorouracil, 336t
 Fluoxetine, 212t
 Fluphenazine, 224t
 Flurazepa, 207t
 Fluticasone, 131t, 136t
 Fluvastatin, 154t
 Folic acid/folate, 420t, 422
 Follicle-stimulating hormone (FSH), 345
 Fondaparinux sodium, 316t
 Food and Nutrition Board of the National Research Council, 425
 Food(s), drug interactions with, 34–35
 Formoterol, 135t
 Fosamprenavir, 117t
 Foscarnet, 112t
 Fraction method, for dosage calculation, 44–45
 Fungal infections, 97–101
 Fungicidal effect, 98
 Fungistatic effect, 98
 Fungus, 74, 97–98
 Furosemide, 146t
 Fusion inhibitors, 117t, 119
G
 Gabapentin, 194t, 247–248, 248b
 Galantamine, for Alzheimer's disease, 186t
 Ganciclovir, 111, 111b, 112t
 Gastric distress, 280
 Gastric motility, 291
 Gastric reflux, 273
 Gastroesophageal reflux disease (GERD), 280b
 drugs for, 280–285, 281t
 nursing considerations for, 283b
 pathophysiology, 281f
 Gastrointestinal problems, drugs for, 271–298
 Gastrointestinal tract
 antacids and, 280–283
 antiemetic drugs and, 273–280, 276b
 protective substance in, 272–273
 proton-pump inhibitors and, 284–285
 serotonin (5-HT₃) receptor antagonists and, 274–276
 stimulants of, 288t
 substance P, 276–277
 Gemcitabine, 336t
 Gemfibrozil, 155
 Gene expression, 331
 General anesthesia, 250–251, 250t
 action, 251
 adverse reactions, 251
 drug interactions, 251
 inhalation agents for, 250–251, 251b
 nursing implications and patient teaching, 251
 side effects, 251
 uses, 251
 Generate solutions, cognitive skills of
 clinical judgment, 10
 Generic equivalent drug, 34

- Generic name, 28
 Gentamicin, 84t
 Genvoya, 117t
 Gestational diabetes, 366
 Giardiasis, 101–102
 Glatiramer, 199t
 Glaucoma, 399–410, 405f
 alpha-adrenergic agonists for, 407–408
 beta-adrenergic antagonists, 404–407
 drugs for, 401–403
 prostaglandin agonist therapy for, 403–404
 Glecaprevir, 113t
 Glimepiride, 367t
 Glipizide, 367t
 Glossitis, 422
 Glucagon, 365, 365b
 Glucocorticoids, 259, 359
 Glucose
 control, blood, 365
 definition of, 365
 Glutamine antagonists, 199–200, 200t
 Glyburide, 367t
 Glycemic control, 365
 Glycerin suppository, 290t
 Glycosylated hemoglobin, 365t
 Goiter, 358
 Gonadotropin-releasing hormone (GnRH), 345
 Gout, 266–267
 antigout drugs, 266–267
 management of, 266
 Gram-negative bacteria, 74
 Gram-positive bacteria, 74
 Granuloma, 91
 Griseofulvin, 98, 99t
 Growth factors, 255
 Guaifenesin, 138, 139t
 Guanylate cyclase-C (GC-C) agonists, 293t
 action and uses, 294
 nursing implications and patient teaching, 294
 side effects/adverse effects, 294
 Gynecomastia, 280, 342–343
- H**
 Half-life, drug, 32
 Hallucinations, 178
 Haloperidol, 224t
 Harvoni, 112
 Healthcare agency policies, in medication regulation, 19–20
 Healthcare workers, protection of, 24
 Healthcare practices, in documenting patient, 413–414
 Healthcare setting, 2–3
 Hearing, 397
 Heart failure, 150
Helicobacter pylori infections, 280
 Helminthiasis, 104
 Helminths, 104
 Hematemesis, 325
 Hematologic system, drugs affecting, 314–330
 Hematuria, 325
 Heparin, 316t
 administration of, 321, 321b
 continuous intravenous therapy with, 321
 Heparin (*Continued*)
 subcutaneous injections of, 321, 321f, 321b
 therapeutic range for, 322
 Heparin-induced thrombocytopenia (HIT), 321
 Heparin-induced thrombocytopenia and thrombosis (HITT), 321
 Hepatitis B virus, antiviral drugs for, 111–113, 113t
 Hepatitis C virus, antiviral drugs for, 111–113, 113t
 Hepatotoxic drug, 33
 Hepatotoxicity, 154
 Herbal products, 416–419
 Herd immunity, 303
 Herpes simplex virus type 1 (HSV-1), antiviral drugs for, 109
 Herpes simplex virus type 2 (HSV-2), antiviral drugs for, 109
 High blood pressure (HBP), 156
 High-alert drugs, 23, 237, 376, 376b
 High-ceiling diuretics, 145
 High-density lipoproteins (HDLs), 151
 High-tyramine foods, to avoid if taking monoamine oxidase inhibitors, 218, 218b
 Histamine, 125
 Histamine H₂-receptor blockers, 281t, 283–284, 284b
 action and uses, 283–284
 adverse reactions, 284
 drug interactions, 284
 nursing implications and patient teaching, 284
 side effects, 284
 HIV replication cycle, 115, 116f
 HIV/AIDS, 115
 Hormonal contraception, 348–350, 349t
 action and uses, 348–349
 adverse effects, 349–350
 drug interactions, 350
 nursing implications and patient teaching, 350
 side effects, 349
 Hormone(s), 345, 354
 interactions for ovulation and menstruation, 346f
 of plenty, 365
 of starvation, 365
 Hormone replacement therapy (HRT), 354–355, 417
 menopausal
 action and uses, 347
 adverse effects, 348
 nursing implications and patient teaching, 348
 side effects, 347
 perimenopausal, 348
 Hormone therapy, 333b
 for breast cancer, 341–342, 341t, 341b
 for prostate cancer, 342–343, 342t
 Hormone-related protein analogs, 388t
 Hospitalist, 4
 Human immunodeficiency virus (HIV), 115
 Human lispro injection, 379t
 Humulin R, 379t
 Hydralazine, 160t
 Hydrochlorothiazide, 146t
 Hydrocodone, 238t
 Hydrocortisol, 260t
 Hydrocortisone, 260t
 Hydromorphone, 238t
 Hydroxychloroquine, 102, 265t
 Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), 151–155
 actions, 152–153
 adverse effects, 153
 drug interactions, 153
 nursing implications and patient teaching, 153–155
 side effects, 153
 uses, 153
 Hydroxyurea, 336t
 Hyperaldosteronism, 360
 Hypercalcemia, 425
 Hypercortisolism, 360
 Hyperglycemia, 365, 366b
 Hyperhidrosis, 216
 Hyperkalemia, 147, 427
 Hyperlipidemia, 150
 Hyperpyrexia, 225
 Hypersensitivities, 33, 81, 125, 320–321
 Hypertension, 144, 150, 156, 356
 Hypertensive crisis, 218–219, 218b
 Hyperthyroidism, 354, 358
 Hypertriglyceridemia, 228
 Hypervitaminosis, 421
 Hypnotics, 206
 Hypocalcemia, 425
 Hypoglycemia, 365
 indications, 368b
 Hypokalemia, 145b, 147, 427
 Hyponatremia, 192, 214, 216, 218
 Hypothermia, 225, 239
 Hypothyroidism, 355
- I**
 Ibandronate, 388t
 Ibuprofen, 257t
 Idarubicin, 337t
 Identifiers, 6
 Idiosyncratic response, to drug, 33
 Ifosfamide, 335t
 Illnesses, drug therapy and, 36
 Imipenem, 79t
 Imipramine, 212t
 Immunity, 300
 Immunization, 302
 drugs for, 299–313
 Immunomodulating therapy, 308–311
 Immunomodulation, 308
 Immunosuppressant drugs, 308
 Impaired nurse, 14
 Implementation, in nursing process, 5–9
 Inactivated vaccines, 302
 Incompatibility, in drug interactions, 34
 Incretin mimetics, 371–373
 Incus, 396
 Indapamide, 146t
 Indinavir, 117t
 Indirect thrombin inhibitors (ITIs), 316t
 actions, 320
 adverse reactions, 320–321
 drug interactions, 321
 nursing implications and patient teaching, 321–322
 side effects, 320
 uses, 320

- Indirect-acting stimuli, 273
- Infants
 calculating drug dosages for, 46
 flow rates for, 48
 opioid agonist analgesics for, 239b
- Infection, 73–75
 anti-infectives, 74–75
 determination, 74
 drug susceptibility and resistance, 75
 general considerations for anti-infective
 drug therapy, 75, 76b–77b
 normal flora, 73–74
 pathogens, 74
- Inflammation, 254, 300
 causes and action, 254–255
 management, 255–266
 symptoms, 254b
- Inflammatory chemical mediators, 254–255
- Influenza, antiviral drugs for, 109–110, 110t
- Inhaled corticosteroids, 136t
- Inhalers
 continuous aerosol therapy, 66, 68f
 dry-powder, 66
 pressurized metered-dose, 66
 types, 68f
- Inhibitory neurotransmitters, 177
- Injection pen, 372t
- Innate immunity, 300, 300b
- Inner ear, anatomy of, 397f
- Inotropic drugs
 action, 171
 adverse reactions, 171–172
 drug interactions, 172
 nursing implications and patient
 teaching, 172
 uses, 171
- Insomnia, 86, 206, 209b, 356
- Instilling, 397
 technique for, 398b
- Institute for Safe Medication Practices (ISMP), 6
- Insulin, 365, 365b
 action and uses, 376–378
 adverse reaction, 378
 dosage of, calculation of, 45–46
 drug interactions, 378
 injection devices, 378
 injection sites, 380–381, 381f
 lack of, 365–366
 nursing implications and patient
 teaching, 380–382
 with pen device, 379b
 regimen, 378
 self-injection, 381b
 side effects, 378
 subcutaneous injection, 378b
 syringe for, 45, 45f
 types of, 46, 378
 units of, 45, 45f
- Insulin apart injection, 379t
- Insulin detemir injection, 379t
- Insulin glargine injection, 379t
- Insulin pen injector, 378f
- Insulin pump, 376, 377f
- Insulin regimen, 378
- Insulin resistance, 228, 366
- Insulin sensitizers, 367, 369–370, 370t
- Insulin stimulators, 367–369, 367t
 action and uses, 367–368
 adverse reactions, 368
 drug interactions, 368
 nursing implications and patient
 teaching, 368–369
 side effects, 368
- Insulin unit, 45
- Insulin-dependent diabetes mellitus (IDDM), 366
- Integrase inhibitors, 117t, 119
- Integrative practices, 414
- Intensive insulin therapy, 376
- Interferon, 111
- Intermediate-acting insulin, 379t
- Intermittent insomnia, 206
- Intermittent pain, 235t
- Intermittent problem, 132
- Internal bleeding, sign of, 323b
- International osteoporosis foundation
 calcium calculator, 385b
- Intradermal injections, 53t, 54–56, 56f
- Intramuscular (IM) route of
 administration, 30
 administration, 53t, 57–58, 58f
 advantages and disadvantages of, 58t
 deltoid, 59f
 vastus lateralis (thigh), 59f
 ventrogluteal, 59f
- Intraocular pressure (IOP), 399
- Intrauterine contraceptives, 349t
- Intravenous anesthetics, 250
- Intravenous (IV) drugs, 58–63
 adding drugs to solution container, 60
 fluid regulation, 61–62
 infusion, 60–61, 61f–62f
 by intermittent (piggyback) infusion, 60
 peripheral IV locks, 60
 push, 60
- Intravenous (IV) infusion
 administration time for, 47, 48b
 calculations for, 46–47
 flow rate for, 47
 infection in, 51
 total infusion time in, 47
- Intravenous (IV) route of administration, 30
- Intravenous (IV) therapy
 allergic reactions in, 63
 completion of, 62
 evaluation for complications of, 62–63, 63t
 fluid overload, 63
 infection and, 63
 infiltration, 63
- Iodoquinol (Yodoxin), 102, 103t
- Ipratropium, 135t
- Irbesartan, 160t
- Irinotecan, 338t
- Iris, 399
- Iron, 426
- Iron deficiency anemia, drugs for, 327–329, 327t
- Iron dextran, 327t, 328–329
- Iron preparations, 327t
- Irritable bowel syndrome (IBS), 273, 286
 drugs for, 292–294, 293t
- Irritant laxatives, 286
- Ischemia, 150
- Isocarboxazid, 212t
- Isoflurane, 250t
- Isoniazid, 92, 93t, 95, 97
- Isophane insulin NPH injection, 379t
- Ivermectin, 104
- J**
- Jaundice, 154
- Jaw, osteonecrosis of, 390f
- Juvenile diabetes, 366
- K**
- Kanamycin, 92–93, 95t
- Kardex, 20–21, 21f
- Kardex drug card, 20–21, 21f
- Keep vein open (KVO), 47
- Ketoacidosis, 366
- Ketoconazole, 99t
- Ketorolac, 257t
- L**
- Labetalol, 160t
- Lacosamide, 193t
 action and uses, 195
 adverse reactions, 195
 drug interactions, 195
 nursing implications and patient
 teaching, 195–196
 side effects, 195
- Lacrimal gland, 399
- Lacrimal sac, 399
- Lactation
 antigout drugs, 267b
 antimetabolites, 336b
 drug therapy and, 37–38
 pregnancy and
 hormonal contraceptives, 350b
 testosterone, 351b
- Lactic acidosis, 120b, 369, 369b
- Lactulose, 290t
- Lamivudine, 111, 117t
- Lamotrigine, 193t
 actions and uses, 194
 adverse reactions, 194
 drug interactions, 194
 nursing implications and patient
 teaching, 194–195
 side effects, 194
- Lansoprazole, 281t
- Lantus insulin, 46
- Laryngeal edema, 78
- Latanoprost, 406t
- Laxatives, 286
 action and uses, 286–287
 adverse effects, 289, 290t
 drug interactions, 289
 nursing implications and patient
 teaching, 290–291
 side effects, 287–289, 290t
 sites of action, 287f
- Ledipasvir, 113t
- Leflunomide, 265t
- Legal prescriptions, 18–19, 18f
- Legal responsibility, 15–17
- Lennox-Gastaut syndrome, 194
- Lethargy, 426
- Leukotriene, 125
- Leukotriene inhibitors, 127t, 129
- Leukotriene receptor antagonists, 127t, 129

- Leukotriene receptor antagonists
(*Continued*)
action, 129
drug interactions, 129
nursing implications and patient teaching, 129–130
side effects and adverse reactions, 129
uses, 129
- Levalbuterol, 135t
- Levemir insulin, 46
- Levetiracetam
actions and uses, 196
adverse reactions, 196–197
drug interactions, 197
nursing implications and patient teaching, 197
side effects, 196–197
- Levobunolol, 406t
- Levocetirizine, 127t
- Levodopa, 180t, 181
- Levofloxacin, 87t
- Levonorgestrel, 349t
- Levothyroxine sodium, 356t
- Lewy bodies, 178
- Licensed practical or vocational nurses.
See LPNs/LVNs
- Lidocaine, 248t, 249, 249b
- Linaclotide, 293t
- Linagliptin, 374t
- Linezolid (Zyvox), 84t, 85, 85b
- Liothyronine sodium, 356t
- Lipid pneumonia, 289
- Lipids, 150
- Lipodystrophy, 378
- Lipoproteins, 151
- Liquid-form oral drugs, 49–50, 49f–50f
- Liraglutide, 372t
- Lisinopril, 160t
- Lithium
for bipolar illness, 220
blood level of, 220
side effects for, 220
therapeutic serum levels, 220, 221t
toxicity
in older adults, 222b
signs and symptoms, 220, 220b
- Lithium carbonate, 221t
- Live vaccine, 302
- Lixisenatide, 372t
- Local/regional anesthetics
action, 249
adverse reactions, 249
drug interactions, 249
drugs, 248–249, 248t
nursing implications and patient teaching, 249–250
side effects, 249
uses, 249
- Lomustine, 335t
- Long-acting beta₂-adrenergic agonist (LABAs), 134, 134b, 135t
- Long-acting insulin analogs, 379t
- Long-acting muscarinic antagonists (LAMAs), 133–134, 135t
- Look-alike, sound-alike drugs, 6
- Loop diuretics, 145, 146t
- Loperamide, 288t
- Lopinavir/ritonavir, 117t
- Loratadine, 127t
- Lorazepam, 207t
- Lovastatin, 154t
- Low-density lipoproteins (LDLs), 151
- Low-molecular-weight heparin (LMWH), 320
deep subcutaneous injection, 321f
- Lozenge, 49, 65
- LPNs/LVNs
role of, nursing process and, 1–10
substance abuse by, 16
- Lubiprostone, 290t, 293t
- Lubricant laxatives, 287, 290t
- Luteinizing hormone (LH), 345
- Luteinizing hormone releasing hormone (LHRH) agonists, 341–342, 341t–342t
- Luteinizing hormone releasing hormone (LHRH) antagonists, 342, 342t
- Lymphocytes, 125
- M**
- Macrodrops, 47
calculation of, 62
chamber, 61f
- Macrolides
actions, 83
adverse effects, 83
drug interactions, 83
expected side effects, 83
nursing implications and patient teaching, 83–85, 84t
uses, 83
- Mad cow disease, 419
- Magnesium, 427
- Magnesium hydroxide, 281t, 290t
- Malaria, 102
- Male sex hormones, 350–352
- Malignant transformation, 332
- Malleus, 396
- Mania, symptoms of, 220b
- Maraviroc, 117t
- Masklike facial expression, 178, 179f
- Mast cell stabilizers (cromones), 127t, 130
- Measles, mumps, and rubella (MMR)
vaccine, 307
- Mechlorethamine, 335t
- Mediators, 125, 254–255
- Medication administration
9 rights of, 20, 20t
ear drops, 66, 67b
enteral, 30, 48–51
evaluation, 9–10, 9b
eye drops and ointments, 66, 67b
intra dermal, 53t, 54–56, 56f
intramuscular (IM), 53t, 57–58, 58f–59f, 58t
nasogastric, 50–51
nine “rights” of, 5–9, 6b, 10b
parenteral, 51–63
percutaneous, 64–70, 64b
percutaneous endoscopic gastrostomy tube, 50–51
principles of, 48
rectal, 68–70, 69b
regulation of, 14–18
federal laws, 14–17
respiratory mucosa, 66, 68t
right documentation in, 9
right dose in, 7
right drug in, 6–7, 7t
right patient in, 6, 6f
- Medication administration (*Continued*)
right reason in, 8–9
right response in, 9
right route in, 7–8
right time in, 8, 8b
right to refuse in, 9
subcutaneous, 53t, 56–57, 56f–57f
systems, nursing process in, 20–21
through mucous membranes, 65–70
topical, 64–65, 65f
transdermal, 64, 65f
vaginal, 66–68, 68b
- Medication administration record (MAR), 48
- Medication cup, for drug administration, 49, 49f
- Medication reconciliation, 23–24
- Medication technician or aides, 19–20
- Medroxyprogesterone, 348t
- Medulla, 359
- Meglitinide, 367t, 368
- Meglitinide analogs, 367t
- Melena, 426
- Meloxicam, 257t
- Melphalan, 335t
- Memantine, 186t
- Menarche, 345
- Menopause, 346–347
drugs for relief of, 347–348, 347b, 348t
increased FSH levels, 347b
reduced estrogen levels, 347b
symptoms of, 347b
- Menstruation, 345, 346f
- Mental health
drugs for, 204–232
neurotransmitters and their functions, 206t
- Mental health–mental illness continuum, 205f
- 6-Mercaptopurine, 336t
- Meropenem, 79t
- Mestranol, 349t
- Metabolism, drug, 31–32, 32f
in older adult, 37
in pediatric patients, 36
- Metastasis, 332–333
- Metered-dose inhaler (MDI), 133f, 136, 137f, 137b
- Metformin, 367t, 369
- Methazolamide, 409t
- Methemoglobinemia, 249
- Methimazole, 356t
- Methocarbamol, 246–247, 246t, 247b
- Methotrexate, 265t, 336t
- Methylcellulose, 288t
- Methyldopa, 160t
- Methylprednisolone, 260t
- Metipranolol, 406t
- Metoclopramide, 181–182, 274t
- Metolazone, 146t
- Metoprolol, 160t
- Metric conversion chart, 44, 44f
- Metronidazole, 103t
action and uses, 102
drug interactions, 102
side effects, 102
- Miconazole nitrate, 99t
- Microdrops, 47
calculation, 62
chamber, 61f

- Microtubules, 339
 Middle ear, 396
 anatomy of, 397f
 Mifepristone, 360–361
 Miglitol (Glyset), 370t
 Milieu, 226
 Mineral oil, 424
 Mineralocorticoid, 359
 Minerals, 425–428
 Mini-pills, 349
 Minocycline hydrochloride, 84t
 Minoxidil, 160t
 Miosis, 191, 239, 399
 MiraLAX or polyethylene glycol 3350, 308
 Miscellaneous analgesics, 244
 Miscellaneous protein synthesis inhibitors, 85
 Misoprostol, 281t, 285
 Mitomycin-C, 337t
 Mitosis, 332
 Mitotane, 360–361, 361t
 Mitotic inhibitors, 339–340, 339t
 actions, 339
 adverse reactions, 339–340
 nursing implications and patient teaching, 340
 side effects, 339
 uses, 339
 Mitoxantrone, 337t–338t
 Mix-o-vials, 54, 56f
 Moderna mRNA vaccines, 308
 Mometasone, 136t
 Monoamine oxidase inhibitors (MAOIs), 34, 212t, 218–219
 action and uses, 218
 adverse effects, 218
 causes, 218b
 drug interactions, 218–219
 high-tyramine foods and drinks to avoid, 218, 218b
 nursing implications and patient teaching, 219
 side effects, 218
 and SSRIs, 219b
 Monoamine oxidase (MAO) type B inhibitors
 action and uses, 183–184
 drug interactions, 184
 nursing implications and patient teaching, 184
 side effects and adverse reactions, 184
 Monoclonal antibodies, 198, 199t
 Monotherapy, 192, 193t
 Montelukast, 127t
 Mood disorders, 210
 Mood stabilizers, 220–222, 221t
 action and uses, 220
 drug interactions, 220–221
 nursing implications and patient teaching, 221–222
 side effects and adverse reactions, 220
 Morphine, 237, 238t, 239
 Moxifloxacin, 92, 93t, 95
 mRNA vaccines, 302, 308
 Mucolytics, 137–138
 action and uses, 137–138
 adverse reactions, 138
 nursing implications and patient teaching, 138, 139t
 side effects, 138
 Multi-drug-resistant (MDR) organism, 75
 Multi-drug-resistant (MDR) tuberculosis, 92–93
 Multiple sclerosis
 drugs for, 197–198
 management, 198
 monoclonal antibodies, 198, 199t
 neurologic drugs for, 198, 199t
 nonspecific anti-inflammatory drugs, 198
 pathogenesis, 197f
 relapsing-remitting, 199t
 specific drugs for, 198
 types, 197–198
 Multiple-dose vials, 54
 Myasthenia gravis
 acetylcholinesterase inhibitors, 200–201
 drugs for, 200–202, 201t
Mycobacterium tuberculosis, 91
 Mycophenolate, 309, 309t
 Mycosis, 74, 97–98
 Mycotic infection, 97–98
 Mydriasis, 399
 Myelin, 197
 Myocardial infarction (MI), 150, 316–317, 325t, 356
 antianginals, 165
 drugs for, 165–172
 nitrates for, 165–167
 Myocardial oxygen demand, 165
 Myocardium, 171
 N
 Nabilone, 274t
 Nabumetone, 257t
 Nadolol, 160t
 Nalbuphine, 238t, 242, 242t, 242b
 Naproxen, 257t
 Narcotics, 237
 Narrow-spectrum drugs, 75
 Nasal corticosteroids, 131, 131t
 Nasal spray, 389
 Nasogastric (NG) tube, 50–51
 Nasolacrimal duct, 399
 Natalizumab, 199t
 Nateglinide, 367t
 National Alliance on Mental Illness (NAMI), 205b
 National Council of State Boards of Nursing (NCSBN), 10
 National Eye Institute (NEI), 400b
 National Institute of Mental Health (NIMH), 226b
 National Institutes of Health, 165b
 Natural penicillins, 78
 Naturally acquired active immunity, 301, 301f
 Naturally acquired passive immunity, 301, 301f
 Nausea and vomiting, 273, 273f, 273b, 334
 Nedocromil sodium, 127t
 Needle-free syringes, 51
 Needleless syringe, for IV injection, 51, 52f
 Negative inotropic drug, 171
 Nelarabine, 336t
 Nelfinavir, 117t
 Neoplasia, 332
 Nephrotoxic drug, 33
 Nephrotoxicity
 aminoglycosides, 85
 in cephalosporins, 81
 Neuraminidase inhibitors, 110t
 Neurokinin 1 receptor antagonists, 274t, 276–277
 Neuroleptic malignant syndrome (NMS), 181, 225
 signs and symptoms, 225, 226b
 Neurologic drugs, 198, 199t
 Neurons, 177
 Neuropathic pain, 234, 235t, 247
 Neurotransmitters, 177, 206t, 274
 excitatory, 177
 inhibitory, 177
 nerve signals by, 177, 178f
 Neutropenia, 318
 Niacin, 155–156, 420t, 421–422
 Nicardipine, 160t
 Nicotinic acid, 155–156
 Nifedipine, 160t
 9 Rights of Drug Administration, 20, 5–9, 6b, 10b, 20t
 documentation, 9
 dose, 7
 drug, 6–7, 7t
 patient, 6, 6f
 reason, 8–9
 refuse, 9
 response, 9
 route, 7–8
 time, 8, 8b
 Nirmatrelvir/ritonavir, 114, 114t
 Nitrates, 165–167
 Nitroglycerin (NTG), 165, 166b
 patch, 65f
 patient education for taking, 166b
 Nizatidine, 281t
 N-methyl-D-aspartate (NMDA) blockers, 186t
 action and uses, 187
 drug interactions, 187
 nursing implications and patient teaching, 187–188
 side effects and adverse reactions, 187
 Nociceptive pain, 234, 235t
 Nomograms, 46
 Nonanthracycline antibiotic agents, 337, 337t
 Non-benzodiazepines, 206
 Non-insulin antidiabetic drugs, 366–367
 alpha-glucosidase inhibitors, 370–371
 biguanides, 369
 categories of, 367
 incretin mimetics, 371–373
 insulin sensitizers, 369–370, 370t
 insulin stimulators, 367–369
 sodium-glucose cotransport inhibitors, 374t
 Non-insulin-dependent diabetes mellitus (NIDDM), 366
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs), 116, 116f, 117t, 119
 Nonopioid centrally acting analgesics, 243–244, 243b
 action, 243
 adverse reactions, 243

- Nonopioid centrally acting analgesics
(*Continued*)
drug interactions, 243
nursing implications and patient teaching, 244
side effects, 243
uses, 243
- Nonpathogens, 73–74
- Nonphenothiazines, 223, 224t
- Nonproprietary name, 28
- Nonselective COX inhibitors, 256
- Nonspecific anti-inflammatory drugs, 198
- Nonstatin antihyperlipidemic drugs, 155
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 245–246, 258b
actions, 256, 256f
adverse reactions, 258
bisphosphonates, 386
cardiovascular risk, 258b
drug interactions, 258
gastrointestinal adverse events, 258b
for inflammatory problems, 257t
nonselective, 256–257, 256f
nursing implications and patient teaching, 258–259
selective, 256, 256f
side effects, 257–258
uses, 256–257
- Norelgestromin, 349t
- Norepinephrine, 159
- Norethindrone, 349t
- Norgestrel, 349t
- Normal cells, 332, 333t
- Normal flora, 73–74
- Normal intraocular pressure (IOP), 401–403
- Normal prostate gland, 149t
- Nortriptyline, 247, 247b
- NPH insulin, 46
- NPH insulin multidose vial, 380f
- Nucleoside reverse transcriptase inhibitors (NRTIs), 111, 116f, 117t, 119, 119b
- Numeric Pain Intensity Scale, 236f
- Nurse Licensure Compact, 19
- Nurse Practice Act, 19
- Nurses
licensed practical/vocational. *See* LPNs/LVNs
registered, responsibility of, 18–19
substance abuse by, 16
- Nursing care plan, 4–5
- Nursing process
assessment in, 2–4, 4b
definition of, 2
diagnosis in, 4
in drug administration systems, 20–21
evaluation in, 9–10, 9b
examples associated with steps, 2f
implementation in, 5–9
LPN practice and, 1–10
planning in, 4–5
- Nystatin, 99t
- O**
- Objective data, 3
- Observation, 3
- Occupational Safety and Health Administration (OSHA) Bloodborne Pathogen, 51
- Ocrelizumab, 199t
- Office of Disease Prevention and Health Promotion, 389b
- Older adults
antihypertensives and, 163b
antithyroid drugs, 359b
beta-adrenergic antagonists, 407b
digoxin and, 172b
drug therapy for, 36–37
absorption as, 36
distribution as, 36–37
elimination as, 37
metabolism as, 37
histamine H₂-receptor blockers, 284b
lithium toxicity in, 222b
nonsteroidal anti-inflammatory drug, 258b
opioid agonist analgesics for, 239b
risk for problems with prescription drugs, 17
selective serotonin reuptake inhibitor, 216b
thyroid hormone agonist drugs, 358b
vaccination, 306b
vitamin K antagonists, 324b
- Oliguria, 239
- Omeprazole, 281t
- Omnibus Budget Reconciliation Acts of 1989, 17
- Oncoviruses, 332
- Ondansetron, 274t
- On/off effect, 181
- Ophthalmic drugs, 398
nursing considerations, 400b
- Opicapone, 180t
- Opioid, 16, 237
- Opioid agonist analgesics, 237–242, 237b, 239b
action, 237–239
adverse reactions, 239, 239b
drug interactions, 240
equianalgesic adult doses, 238t
nursing implications and patient teaching, 240–242
opioid-induced constipation, 239, 239b
side effects, 239
tolerance, dependence, and substance use disorder, 240
uses, 239
- Opioid agonist-antagonist analgesics, 238t, 242–243, 242t
action, 242
adverse reactions, 242–243
drug interactions, 243
nursing implications and patient teaching, 243
side effects, 242
uses, 242
- Opioid agonists, 237–238, 238t, 291, 293t
action and uses, 294
nursing implications and patient teaching, 294
side effects/adverse effects, 294
- Opioid antitussives, 140
- Opioid misuse disorder, 240
- Opioid receptors, 238b
- Opportunistic infections, 98, 115
- Optic neuritis, 102
- Oral contraceptives, 348, 349t, 422
- Oral corticosteroids, 245, 260t, 262f
- Oral drugs, 49–50
for infant or child, 49–50, 50f
liquid-form, 49–50, 49f–50f
tablets or capsules, 49
- Oral hypoglycemic agents, 366–367
- Oral sympathomimetic decongestants, 130
- Orthostatic hypotension, 390
- Oseltamivir, 110t
- Osmotic laxatives, 287, 288t, 290t, 290b
- Osteoblasts, 385
- Osteoclast monoclonal antibodies, 388t, 390–391
action, 390
adverse effects, 390
nursing implications and patient teaching, 390–391
side effects, 390
uses, 390
- Osteoclasts, 385
- Osteocytes, 385
- Osteomalacia, 425
- Osteonecrosis, of jaw, 390f
- Osteopenia, 384
- Osteoporosis
bone loss comparison, 386f
bone mass and, 387b
drugs for, 384–395, 388t
bisphosphonates, 386–387
calcitonin, 389
calcium and vitamin D, 391–392
osteoclast monoclonal antibodies, 390–391
parathyroid hormone analogs and parathyroid hormone-related protein analogs, 389–390
sclerostin inhibitors, 391
selective estrogen receptor modulators, 387–389
risk factors for, 385b
risk of, 387b
vertebral body, 386f
- Otic drugs, 397
- Otitis media, 396
- Ototoxicity, aminoglycosides, 85
- Outbreaks, 109
- Oval window, 396
- Overactive bladder (OAB), 148–149
drugs for, 148–149
pathophysiology, 150f
- Overactive thyroid, 358
- Over-the-counter (OTC) drugs, 14, 17, 413–416
active ingredients, 416t
nonprescription, 414
patient teaching, 415–416
product labeling, 414, 415f
- Ovulation, 345, 346f
- Oxaliplatin, 335t
- Oxaprozin, 257t
- Oxcarbazepine
actions and uses, 192
drug interactions, 192
nursing implications and patient teaching, 192–194, 193t
side effects and adverse reactions, 192
- Oxybutynin, 151t
- Oxycodone, 238t
- Oxymetazoline, 131t
- Oxymorphone, 238t

P

- Paclitaxel, 339t
- Pain
- acute, 235t
 - assessment, 241b
 - breakthrough, 239
 - cancer, 235t
 - chronic, 235t
 - classification, 234, 235t
 - continuous, 235t
 - definition, 234
 - intermittent, 234, 235t
 - measurement scales, 236f
 - neuropathic, 235t
 - nociceptive, 235t
 - perception, 235
 - radicular, 234, 235t
 - visceral, 235t
- Pain management
- analgesic drugs for, 236–244
 - antidepressants for, 247, 247b–248b
 - miscellaneous drugs for, 244–251, 244b
 - principles of, 235
- Pain threshold, 234
- Palivizumab, 112t
- Palpation, 3
- Pancreatitis, 120b
- Pantoprazole, 281t
- Paradoxical response, to drug, 33
- Parasite, 74, 101
- Parasitic infections, 101–105
- Parathyroid hormone analogs, 388t, 389–390
- action, 389–390
 - adverse effects, 390
 - nursing implications and patient teaching, 390
 - side effects, 390
 - uses, 389–390
- Parathyroid hormone-related protein analogs, 389–390
- action, 389–390
 - adverse effects, 390
 - nursing implications and patient teaching, 390
 - side effects, 390
 - uses, 389–390
- Parenteral corticosteroids, 260t
- Parenteral route of administration, 30, 51–63
- mixing, 54
 - needles for, 52, 53f, 53t
 - preparation of, 53–54
 - principles for, 51–52
 - procedure for, 52–63, 54b
 - syringes for, 51–52, 53f
- Paresthesias, 427
- Parkinson's disease (PD)
- catechol-*O*-methyltransferase (COMT) inhibitors, 183
 - clinical trials and research into, 178b
 - complications of, 178
 - diagnosis, 178
 - dopamine agonists, 179–183
 - drugs for, 178–184, 179b, 180t
 - masklike facial expression, 178, 179f
 - monoamine oxidase type B inhibitors, 183–184
 - neurotransmitter abnormality, 178, 179f
 - symptoms, 179b
- Paroxetine, 212t, 247, 247b
- Partial agonists, 29, 29b
- Passive immunity, 301
- Pathogen, 74
- Patient and family teaching
- acetaminophen, 245
 - alkylating agents, 335
 - antacids, 283
 - antianxiety drugs, 210
 - antidiarrheals, 292
 - antigout drugs, 267
 - antimetabolites, 336–337
 - antithyroid drugs, 359
 - antitubercular drugs, 97
 - antitumor antibiotics, 338
 - antitussives, 140
 - atypical antipsychotic drugs, 228–229
 - beta-adrenergic antagonists, 407
 - bronchodilators, 136–137
 - cannabinoids, 279
 - chloride channel activators, 293–294
 - cholinergic drugs, 409
 - corticosteroids, 263–264
 - direct thrombin inhibitors, 320
 - disease-modifying antirheumatic drug, 266
 - erythropoiesis-stimulating agents, 327
 - ferrous sulfate, 328
 - fibrinolytic drugs, 326
 - general anesthesia, 251
 - guanylate cyclase-C agonists, 294
 - histamine H₂-receptor blockers, 284
 - insulin, 381–382
 - iron dextran, 329
 - laxatives, 290–291
 - local/regional anesthetics, 250
 - mitotic inhibitors, 340
 - monoamine oxidase inhibitors, 219
 - mood stabilizers, 222
 - nonsteroidal anti-inflammatory drugs, 259
 - on opioid agonist analgesics, 241–242
 - opioid agonists, 294
 - phenothiazines, 278
 - promotility drugs, 279–280
 - prostaglandin agonists, 404
 - proton-pump inhibitors, 285
 - sedative-hypnotics, 208
 - selective immunosuppressants for transplant rejection, 311
 - selective serotonin (5-HT₄) agonists, 294
 - selective serotonin reuptake inhibitors, 215–216
 - serotonin (5-HT₃) receptor antagonists, 276
 - serotonin-norepinephrine reuptake inhibitor, 217
 - skeletal muscle relaxants, 247
 - substance P/neurokinin 1 receptor antagonists, 277
 - thyroid hormone agonists, 355–358
 - topoisomerase inhibitors, 339
 - tricyclic antidepressants, 218
 - typical antipsychotics, 227
 - vaccine, 307
 - vesicular monoamine transporter 2 inhibitors, 230
 - vitamin K antagonists, 324
- Patient charts, 16–17
- Peak, 85
- Pediatric patient(s)
- acetaminophen, 245b
 - aspirin, 258b
 - calculating drug dosages for, 46
 - drug therapy for
 - absorption as, 35–36
 - distribution as, 36
 - elimination as, 36
 - metabolism as, 36
 - overview, 35
 - flow rates for, 48
 - hypothyroidism, 355
 - liver toxicity, 192b
 - mucolytics, 138b
 - pain assessment for, 241b
 - thyroid hormone agonist drugs, 357b
- Pediatric vaccination, 306b
- Peginterferon alfa-2b, 111
- Pemetrexed, 336t
- Penciclovir, 110t
- Penicillin G benzathine, 79t
- Penicillin G procaine, 79t
- Penicillin V potassium, 79t
- Penicillinase-resistant penicillins, 78
- Penicillins, 78b
- action, 77
 - adverse reactions, 78
 - bacteriostatic action on bacterial pathogens, 76–77, 77f
 - drug interactions, 78
 - natural, 78
 - nursing implications and patient teaching, 79t, 81, 81b
 - penicillinase-resistant, 78
 - side effects, 78
 - uses, 78
- Pentazocine, 238t, 242, 242t, 242b
- Pentostatin, 336t
- Peptic ulcer disease (PUD), 280, 280b
- drugs for, 280–285, 281t
 - nursing considerations for, 283b
 - pathophysiology, 280f
- Peramivir, 110t
- Percutaneous drugs, 64–70, 64b
- Percutaneous endoscopic gastrostomy (PEG) tube administration, 50–51, 51b
- Percutaneous route of administration, 30
- Perimenopause, 346
- Peripheral nervous system (PNS), 177
- Peripheral neuropathy, 87–88, 339
- symptoms, 102
- Peripheral (side) vision and blindness, 400, 405f
- Personal factors, causes cancer, 332
- Petechiae, 319f, 335
- PFIZER-BioNTech mRNA COVID vaccine, 308
- Pharmaceutical insulin, 379t
- Pharmacodynamics, 28
- Pharmacokinetics, 28
- process of, 32b
- Pharmacology, 1–12
- drug attachment, 28–29
 - drug names in, 28
 - principles, 27–42
- Pharmacotherapeutics, 28
- Phenazopyridine, 148
- Phenelzine, 212t

- Phenobarbital, 190t
actions and uses, 191
adverse reactions, 191
side effects, 191
- Phenothiazines, 223, 224t, 274t, 277–278
action and uses, 277
adverse reactions, 277–278
drug interactions, 278
nursing implications and patient teaching, 278
side effects, 277
- Phenylephrine, 131t
- Phenytoin, 190t
actions and uses, 189
adverse reactions, 191
dopamine agonists and, 181–182
- Physical dependence, 15b
- Phytic acid, 425–426
- Phytoestrogens, 417
- Piggyback infusion, 60
- Pigments, 399
- Pill, 48–49
- Pilocarpine, 407t
- Pimavanserin, 179
- Pinna, 396, 397f
- Pioglitazone, 370t
- Piperazine penicillin, 78
- Pirbuterol, 135t
- Piroxicam, 257t
- Planning
to give drug, factors to consider in, 5
in nursing process, 4–5
- Plant alkaloids, 338
- Platelet inhibitors, 316–319, 316t
action, 316–317
adverse reactions, 318
drug and food interactions, 318
nursing implications and patient teaching, 318–319
side effects, 318
uses, 317–318
- Plavix. *See* Clopidogrel
- Pletal. *See* Cilostazol
- Polydipsia, 366
- Polyenes, 99t
- Polyethylene glycol, 288t, 290t
- Polyphagia, 366
- Polypharmacy, 366
- Polyuria, 366
- Porous bone, 384
- Positive inotropic drug, 171
- Postattachment inhibitors, 117t, 119
- Posterior chamber, 399
- Posterior segment, eye, 399–400
- Postural hypotension, 139–140, 422
- Potassium, 145, 427
- Potassium channel blockers, 169t
- Potassium-sparing diuretics, 145, 146t
- Pradaxa. *See* Dabigatran
- Pralatrexate, 336t
- Pramipexole, 180t
- Pramlintide, 372t
- Pravastatin, 154t
- Praziquantel, 103t, 104–105
- Prazosin, 160t
- Precautions, 5
- Precursor, 419
- Prediabetes, 366
- Prednisolone, 259b, 260t
- Prednisone, 259b, 260t
- Pre-exposure prophylaxis (PrEP), 120
- Prefilled syringes, 54, 56f
- Pregabalin, 194t, 247–248, 248b
- Pregnancy, 192b
antigout drugs, 267b
antimetabolites, 336b
antithyroid drugs, 359b
benzodiazepines, 208b
drug therapy and, 37–38
and lactation
hormonal contraceptives, 350b
testosterone, 351b
lidocaine, 249b
and selective immunosuppressants, 311b
vaccination, 306b
- Prehypertension, 156
- Prescription drugs, 14, 17
- Prescriptive authority, 18
- Pressurized metered-dose inhaler, 66
- Prilocaine, 248–249, 248t, 249b
- Primaquine, 102, 103t
- Primary hypertension, 156
- Primary open-angle closure, 400
- Primary tumor, 332
- Primidone, 190t
actions and uses, 191
adverse reactions, 191
side effects, 191
- Prochlorperazine, 274t
- Prodrugs, 31
- Professional responsibility, 19
- Progesterone
drugs, 348
secretion, feedback loops controlling, 345–346, 346f
- Prokinetic drugs, 279
- Promethazine, 274t
- Promotility drugs, 274t, 279–280
action and uses, 279
adverse reactions, 279
drug interactions, 279
nursing implications and patient teaching, 279–280
side effects, 279
- Propafenone, 169t
- Proportion method, in calculating drug dosages, 45
- Propranolol, 160t
- Proprietary or Patent Medicine Act, 18
- Propylthiouracil, 356t
- Prostaglandin agonists, 406t
action and uses, 403
adverse reactions, 404
nursing implications and patient teaching, 404
side effects, 404, 406f
- Prostaglandin analogs, 401–403
- Prostaglandins, 272–273, 280b
- Prostate cancer, hormone therapy for, 342–343
adverse and side effects, 342–343
drug categories, 342, 342t
- Prostate gland, 149f
- Protease inhibitors, 112–114, 113t, 116f, 117t, 119
- Protein synthesis inhibitors, 82, 85
- Prothrombin, 315
- Protocols, 333
- Proton-pump inhibitors (PPIs), 281t, 284–285, 284b
action and uses, 284
adverse reactions, 284
drug interactions, 285
nursing implications and patient teaching, 285
side effects, 284
- Protozoa, 101–102
- Provitamin, 419
- Pruritus, 318
- Pseudoephedrine, 131t, 139–140
- Pseudomembranous colitis, 76b
- Pseudoparkinsonism, 223–225, 226f
- Psychological dependence, 15b
- Psychosis, 222–223
- Psyllium, 288t, 290t
- Pulmonary embolism (PE), 319, 325t
- Pulmonary fibrosis, 337
- Punctal occlusion, 401f
- Pupil, 399
- Pupil sizes comparison, 404f
- Purpura, 318
- Pyrantel, 104
- Pyrazinamide, 92, 93t, 95
- Pyridostigmine, 201, 201t
- Pyridostigmine bromide, 201t
- Pyridoxine, 420t, 422
- Pyridoxine deficiency, 422
- Pyrimethamine, 102
- Pyxis (BD Pyxis MedStation), 21, 22f
- Q**
- QT interval, 228
- Quetiapine, 224t
- Quinapril, 160t
- Quinidine, 169t
- R**
- Rabies, and artificial acquired passive immunity, 302
- Radiation therapy, 333b
- Radicava, 200, 200t
- Radicular pain, 234, 235t
- Raltegravir, 117t
- Rapid-acting insulin analogs, 379t
- Rasagiline, 180t
- Rash, 191b
- Ratio method, in calculating drug dosages, 45
- Receptor site, drug, 28–29, 29f
- Recommended dietary allowances (RDAs), 419
- Rectal drug administration, 68–70, 69b
- Red man syndrome, 82
- Reference daily intake (RDI), 419
- Registered nurse, responsibility of, 18–19
- Regular human insulin injection, 379t
- Relapsing-remitting multiple sclerosis (RRMS), 197–198, 199t
- Reliever, 134
- Remdesivir, 114t
- Renal system, drugs affecting, 144
- Renin, 158
- Renin-angiotensin-aldosterone system (RAAS) drugs, 158–159, 160t
- Repaglinide, 367t
- Reproductive health, drugs for, 345–353
- Resistant organisms, 75

- Respiratory depression, 239
 Respiratory problems, drugs for, 124–142
 Respiratory syncytial virus (RSV), 110–111
 Respiratory system, 126f
 Reteplase, 325t
 Reticulocytes, 327
 Retina, 400
 Retroviruses, 115
 Reye's syndrome, 246, 246b, 258
 Rhabdomyolysis, 153
 Ribavirin (Virazole), 111, 112t
 Riboflavin, 420t, 421
 Rifampin, 92, 93t, 95, 97
 Rifapentine, 92, 93t, 95
 Rifater, 95
 Rilpivirine, 117t
 Riluzole, 199, 200t
 Rimantadine, 109
 Risedronate, 388t
 Risperidone, 181b, 224t
 Rivaroxaban, 316t, 319
 Rivastigmine, for Alzheimer's disease, 186t
 Rolapitant, 274t
 Romosozumab, 388t
 Ropinirole, 180t, 181b
 Rosiglitazone (Avandia), 370t
 Rosuvastatin, 154t
 Rotigotine, 180t
 Route of administration
 enteral, 30, 48–51
 nasogastric, 50–51
 oral, 49–50
 intramuscular (IM), 30, 53t, 57–58, 58f–59f, 58t
 intravenous (IV), 30
 parenteral, 30
 mixing, 54
 needles for, 52, 53f, 53t
 preparation of, 53–54
 principles for, 51–52
 procedure for, 52–63, 54b
 syringes for, 51–52, 53f
 percutaneous, 30
 subcutaneous, 30
 sublingual, 30, 65, 67b
 topical, 30
 Rufinamide, 194t
 Rukobia, 117t
 Runner's high, 417–418
 Rytary, 180t
- S**
 Saffinamide, 180t
 Saline laxatives, 286–287
 Salmeterol, 135t
 Saquinavir, 117t
 Saxagliptin, 374t
 Scheduled drugs, 14–15
 Schizophrenia, 223b
 Sclerostin inhibitor, 388t, 391
 action, 391
 adverse effects, 391
 nursing implications and patient teaching, 391
 side effects, 391
 uses, 391
 Seasonal influenza vaccination, 305–306
- Second generation antipsychotics, 227, 227b
 Secondary hypertension, 156
 Secondary infection, 74
 Secondary tuberculosis (TB), 91
 Second-generation antihistamines, 127t
 Second-generation sulfonylurea agents, 367t
 Sedation, 239, 240b
 Sedative, 206
 Sedative-hypnotics, 206–208
 action and uses, 206–208
 drug interactions, 208
 nursing implications and patient teaching, 208
 side effects and adverse reactions, 208
 Seizures, 188
 classification, 188, 188b
 generalized, 188
 partial, 188
 Selective alpha₁ blockers, 149t
 Selective cholesterol absorption inhibitors, 155
 Selective estrogen receptor modulators (SERMs), 341, 341t, 387–389, 388t
 action, 387
 adverse effects, 387
 nursing implications and patient teaching, 387
 side effects, 387
 uses, 387
 Selective immunosuppressants, 309t
 for autoimmune diseases, 308
 transplant rejection prevention, 308–311
 action, 308–310
 adverse effects, 310
 drug interactions, 310
 nursing implications and patient teaching, 310–311
 side effects, 310
 Selective MAO-B inhibitors, 180t
 Selective serotonin (5-HT₄) agonists, 293t
 action and uses, 294
 nursing implications and patient teaching, 294
 side effects/adverse effects, 294
 Selective serotonin reuptake inhibitor (SSRI), 211–216, 212f, 212t, 216b
 action and uses, 211
 for anxiety, 209
 drug interactions, 214–215
 nursing implications and patient teaching, 215–216
 side effects and adverse reactions, 211–214
 Selegiline, 180t, 212t
 Semicircular canals, 396–397
 Serotonin (5-HT₃) receptor antagonists, 274–276, 274t, 274b
 action and uses, 274
 adverse reactions, 276
 drug interactions, 276
 nursing implications and patient teaching, 276
 side effects, 274–276
 Serotonin syndrome, 214
 signs and symptoms of, 215b
- Serotonin-norepinephrine reuptake inhibitors (SNRIs), 212t, 216–217
 action and uses, 216
 for anxiety, 209
 drug interactions, 216
 nursing implications and patient teaching, 216–217
 side effects and adverse reactions, 216
 Sertraline, 212t, 247, 247b
 Setrons, 274
 Sevoflurane, 250t
 Short-acting beta₂-adrenergic agonist (SABA), 134, 134b, 135t
 Short-acting insulin, 379t
 Side effect, 33
 Silodosin, 149t
 Simeprevir, 113t
 Simple Descriptive Pain Intensity Scale, 236f
 Sinemet, 180t
 Single drug order, 19
 Sirolimus, 309, 309t
 Sitagliptin, 374t
 Skeletal muscle relaxants, 246–247, 246t
 action, 246
 adverse effects, 246–247
 drug interactions, 247
 nursing implications and patient teaching, 247
 side effects, 246
 uses, 246
 Skeletal muscle spasm, 246
 Sleep, drugs for, 206–210
 Sodium channel blockers, 169t
 Sodium phosphate, 290t
 Sodium phosphate monobasic monohydrate/sodium phosphate dibasic anhydrous, 288t
 Sodium-glucose cotransport inhibitors, 374t, 375–376
 Sofosbuvir/velpatasvir, 113t
 Solifenacin, 151t
 Solubility, of medications, 30
 Sotalol, 169t
 Spectrum, 75
 Spironolactone, 146t
 St. John's wort, 417
 Standing drug order, 19
 Stapes, 396
 State law, on medications, 19–20
 Statins, 154
 Stavudine, 117t
 Steroid production inhibitors, 361t
 Stevens-Johnson syndrome, 98, 191
 Stimulant laxatives, 287, 290b
 Stimulants, 288t, 290t
 Stomatitis, 86, 422
 Stool softeners, 286–287, 290t
 "Streptococcus-234" bacteria, 300–301
 Streptomycin, 84t
 Stribild, 117t
 Stroke, 325t
 Student Study Guide, 44
 Subcutaneous (route) administration, 30
 Subcutaneous heparin, 321, 321b
 Subcutaneous implants, 349t
 Subcutaneous injections, 53t, 56–57, 56f–57f
 Subjective data, 3

Sublingual route of administration, 30, 65, 67b
 Substance abuse and misuse, 14
 Substance P/neurokinin 1 receptor antagonists, 274t, 276–277
 action and uses, 276–277
 adverse reactions, 277
 drug interactions, 277
 nursing implications and patient teaching, 277
 side effects, 277
 Substance use disorder, 240
 Substantia nigra, 178
 Sucralfate, 281t, 285
 Suicidal ideation, 217
 Sulfamethoxazole/trimethoprim, 87t
 Sulfasalazine, 265t
 Sulfonamides
 actions, 86
 adverse reactions, 86
 drug interactions, 86
 nursing implications and patient teaching, 86, 87t
 side effects, 86
 uses, 86
 Sulfonylureas, 368
 Superbug, 75
 Superinfection, 74
 Suppressor gene products, 332
 Sympathomimetic nasal decongestants, 130–131
 Sympathomimetics, 130, 131t
 Synapse, 177
 Synergistic effect, in drug interaction, 34
 Synthetic opioid agonists, 288t
 Syringes
 insulin, 45, 45f
 for parenteral drugs, 51–52, 53f
 prefilled, 54, 56f

T

Tablets, 49
 crushing, 14
 Tachycardia, 191
 Tacrolimus, 309t
 Tall Man lettering system, 6, 7t
 Tamsulosin, 149t
 Tapering, 261–262
 Tardive dyskinesia, 182, 223–225, 226f, 229–230, 229t
 Target tissue, 354
 Taxanes, 339, 339t
 Telbivudine, 113t
 Temazepam, 207t
 Temozolomide, 335t
 Tenecteplase, 325t
 Teniposide, 338t
 Tenofovir, 117t
 Tensilon (edrophonium) test, 201
 Teratogen, 191
 Teratogenic, 100
 Terazosin, 149t, 160t
 Terbinafine (Lamisil), 98
 Teriflunomide, 199t
 Teriparatide, 388t
 Testosterone, 350, 351t, 351b
 Testosterone enanthate subcutaneous injection, 351t
 Testosterone gel, 351t
 Testosterone mouth patch, 351t

Testosterone pellets, 351t
 Testosterone transdermal patch, 351t
 Tetracyclines, 83b
 action, 82
 adverse effects, 82–83
 drug interactions, 83, 84t
 side effects, 82
 uses, 82
 9-Tetrahydrocannabinol (THC), 418
 The Joint Commission (TJC), official do not use list, 23t
 Therapeutic effects, 9–10
 Thiamine, 420t, 421
 Thiazide diuretics, 146t
 Thiazolidinediones, 370t
 Thioguanine, 336t
 Thiotepa, 335t
 Throbbing headaches, 165
 Thrombi, 315
 Thrombin, 315
 Thrombocytopenia, 318
 Thrombolytic drugs, 324
 Thrombophlebitis, 315
 Thromboplastin, 315
 Thrombus, 315
 Thrush, 100–101
 Thyroid crisis, 358
 Thyroid hormone agonists, 355–358
 action and uses, 355–356
 adverse effects, 356
 drug interactions, 356
 nursing implications and patient teaching, 356–358
 side effects, 356
 Thyroid problems
 drugs for, 355–359, 355f, 355b
 symptoms associated, 355, 355b
 Thyroid storm, 358
 Thyrotoxicosis, 358
 Thyrotropin-releasing hormone (TRH), 354

Tiagabine, 194t
 Ticagrelor, 316t
 Ticlopidine, 316t
 Timolol, 406t
 Tinnitus, 86
 Tinzaparin, 316t
 Tiotropium, 135t
 Tipranavir, 117t
 To keep open (TKO), 47
 Tocilizumab, 265t
 Tolcapone, 180t
 Tolerance, 240
 Tolterodine, 151t
 Topical corticosteroids, 260t
 Topical drugs, 64–65, 65f
 Topical eye drug therapy, 401b
 Topical route of administration, 30
 Topiramate, 193t
 actions and uses, 196
 adverse reactions, 196
 drug interactions, 196
 nursing implications and patient teaching, 196
 side effects, 196
 Topoisomerase inhibitors, 338–339, 338t
 action, 338
 adverse reactions, 338
 nursing implications and patient teaching, 338–339

Topoisomerase inhibitors (*Continued*)
 side effects, 338
 types of, 338
 uses, 338
 Topoisomerase I inhibitors, 338t
 Topoisomerase II inhibitors, 338t
 Topotecan, 338t
 Torsade de pointes, 186–187, 427
 Toxoids, 302
 Toxoplasmosis, 102
 Trabectedin, 335t
 Trade name, 28
 Traditional chemotherapy, 334–341
 Tramadol, 243–244, 243b
 Transcriptase, 115
 Transdermal patches, 64, 65f
 Travoprost, 406t
 Triamcinolone, 131t, 260t
 Triamterene, 146t
 Trichomoniasis, 102
 Tricyclic antidepressants (TCAs), 212t, 217–218
 action and uses, 217
 adverse reactions, 217
 drug interactions, 217
 nursing implications and patient teaching, 217–218
 side effects, 217
 Trimethobenzamide, 274t
 Triumeq, 117t
 Tropicium chloride, 151t
 Trough, 85
 Trousseau sign, 426
 Truvada, 117t
 Tuberculin tests, 56
 Tuberculosis (TB), 91–97, 92f
 drug therapy for, 93t
 parenteral drug therapy, 95t
 sites of drug activity on TB organism, 95, 96f
 symptoms, 92b
 Tympanic membrane, 396
 Type 1 diabetes mellitus, 366
 Typical antipsychotics, 223–227, 224t
 action and uses, 223
 drug interactions, 225
 nursing implications and patient teaching, 225–227
 side effects and adverse reactions, 223–225
 Tyramine, foods that contain, 184b

U

U-100 and U-50 syringes, 45f, 377f
 Ulcer, peptic. *See* Peptic ulcer disease
 Uncoating inhibitors, 110t
 Underactive thyroid, 355
 Unit-dose drugs, 44
 Unit-dose system, 20–21
 United States, drug regulations in, 14–18, 15t
 federal laws, 14–17
 healthcare agency policies, 19–20
 state law in, 19–20
 Ureidopenicillins, 78
 Urgency, 148–149
 Uric acid synthesis inhibitors, for gout, 267t
 Urinary antispasmodics, 149
 Urinary incontinence, 148–149

- Urinary system, 144–149
 bladder anesthetics, 148–149
 diuretics and, 144–148
 drugs affecting, 144–149
Urticaria, 78
- V**
- Vaccination, 302–308
 adults, 303, 305f, 306b
 booster schedules, 303–304
 children, 303, 304f
 COVID-19, 307–308
 pediatric, 306b
 and pregnancy, 306b
 seasonal influenza, 305–306
- Vaccine, 302
 administration, responsibilities and
 actions for, 306b
 adverse reactions, 307
 measles, mumps, and rubella, 307
 nursing implications and patient
 teaching, 307
 side effects, 306
 types, 302–303, 303b
- Vaginal drugs, 66–68, 68b
- Valacyclovir, 110t
- Valbenazine (Ingrezza), 229t
- Valganciclovir, 111, 111b, 112t
- Valproic acid, 190t
 actions and uses, 191
 adverse reactions, 191
 side effects, 191
- Valrubicin, 337t
- Valsartan, 160t
- Vancomycin, 79t, 82
- Vancomycin-resistant enterococci (VRE),
 82
- Vancomycin-resistant *Staphylococcus*
 aureus (VRSA), 85
- Vasodilators, 158
- Venlafaxine, 212t
- Ventricular tachycardia, 427
- Verapamil, 160t, 169t
- Verbal order, 18–19
- Vertigo, 86
- Vesicular monoamine transporter 2
 (VMAT2) inhibitors, 229–230
 action and uses, 229
 assessment of, 229
 drug interactions, 229
 drug/adult dosage, 229t
 evaluation, 230
 nursing implications for, 229t
 planning and implementation, 229
 side effects and adverse reactions,
 229
- Vestibule, 396–397
- Vestibulocochlear nerve, 396–397
- Vials
 insulin, 45, 45f
 Mix-o-Vial, 54, 56f
 multiple-dose, 54
 for parenteral drugs, 53–54
- Vigabatrin, 194t
- Vinca alkaloids, 339, 339t
- Viral DNA polymerase inhibitors, 110t
- Viral vector vaccines, 303
- Virions, 109
- Virus, 74, 109
- Visceral pain, 235t
- Visual Analogue Scale (VAS), 236f
- Vitamin A, 420t, 421
- Vitamin B₁, 420t, 421
- Vitamin B₂, 420t, 421–422
- Vitamin B₃, 421–422
- Vitamin B₆, 420t, 422
 carbidopa/levodopa and, 181–182
- Vitamin B₉, 422
- Vitamin B₁₂, 420t, 422–423
- Vitamin C, 420t, 423–424
- Vitamin D, 391–392, 420t, 424
 action, 391
 adverse effects, 391
 nursing implications and patient
 teaching, 391–392
 side effects, 391
 uses, 391
- Vitamin E, 420t, 424–425
- Vitamin K, 315, 420t, 425
- Vitamin K antagonists, 316t, 322–324
 actions, 322
 adverse reactions, 322–323
 drug and food interactions, 323
 nursing implications and patient
 teaching, 323–324
 side effects, 322
 uses, 322
- Vitamins
 fat-soluble, 419, 420t
 function and deficiency, 420t
 reference daily intake value, 420t
 water-soluble, 419, 420t
- Vitreous humor, 400
- Vomiting, 273f
- W**
- Warfarin (Coumadin), 316t
- Warfarin-induced skin necrosis, 323f
- Water-soluble vitamins, 419, 420t
- Wearing off, 181
- Weight, body, drug therapy and, 35
- Withdrawal symptoms, 240
- Wong-Baker FACES pain rating scale,
 236f
- Wound healing, 423
- Wristband, electronic scan of, 20f
- X**
- Xanthine-based drugs, 134
- Z**
- Z track technique, 58, 60f
- Zafirlukast, 127t
- Zaleplon, 207t
- Zanamivir, 110t
- Zidovudine, 117t
- Zileuto, 127t
- Zinc, 427–428
- Ziprasidone, 224t
- Zoledronic acid, 388t
- Zolpidem, 207t
- Zonisamide, 194t